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Abstract
Tumor and metastasis formation are not cell autonomous phenomena, but rather an
evolution of disease within and responding to the host environment. Metastatic spread
from a primary tumor occurs as a result of a complex interplay between tumor cells and
the host, wherein tumor cells must escape the primary tumor, enter the host vasculature,
travel to and arrest in a distant tissue and survive and grow in that new organ. It is known
that cells that progress through these stages must both escape and exploit host systems,
yet the mechanisms used are not fully understood. Therefore, the goal of this work was
to investigate the interactions between tumor cells and the host and to determine the role
that host systems play in supporting tumor development and progression. Specifically,
the interaction between hemostatic factors and metastatic cells was evaluated, and the
effect of a primary tumor in influencing this interaction was investigated using a murine
melanoma cell line. It was determined that tumor cells are capable of exploiting host
hemostatic factors to increase lung metastasis, and stabilization of this interaction
increased metastasis. Intriguingly, the presence of a primary tumor depleted circulating
platelets leading to impaired hemostasis at the time of metastatic cell introduction. This
led to reduced interaction between tumor cells and host hemostatic factors and decreased
metastasis. To determine if this effect of a primary tumor was unique to melanoma, a
human breast adenocarcinoma cell line was also used. In agreement with murine
melanoma data, it was found that the presence of a breast primary tumor also reduced the
development of lung metastases. The ability of metastatic cells to exploit host hemostatic
factors and the identification of global modulation of this interaction by a primary tumor
indicates that the interaction between primary tumor, host, and distant metastatic cells is
complex and multi-faceted. Full understanding of the interplay between a primary tumor,
the host and metastases will be essential to the development of strategies to inhibit
metastatic progression, either before or after the surgical resection of the primary tumor.
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Chapter 1

1

Introduction

Cancer was responsible for 7.9 million deaths in 2007, accounting for approximately 13%
of all deaths worldwide. This number is expected to climb to over 11 million deaths by
20301. Importantly, primary tumor formation is not generally responsible for this high
level of mortality. Rather, the spread of tumor cells throughout the body in a process
known as metastasis leads to the majority of cancer-related deaths2. In this thesis I will
focus on how tumor cells are capable of exploiting host cells, growth factors, pathways
and systems during each of the key steps in metastasis.

1.1 Cancer is a disease of cell and host
Tumor formation is not a cell autonomous phenomenon, but rather an evolution of
disease within and responding to the host environment. In particular, metastatic spread
from a primary tumor occurs as a result of a complex interplay between tumor cells and
the host. In order to form successful metastases, tumor cells must escape the primary
tumor, enter the host vasculature, travel to and arrest in a distant tissue and survive and
grow in that new organ2. Cells that progress through these stages must both escape and
exploit host systems.
As tumor cells acquire a metastatic phenotype, they do so through interacting with and
manipulating host responses3-5. The tissue microenvironment is significantly altered by
the presence of a primary tumor, with changes in stromal cell composition and the
presence of infiltrating immune cells. The individual components are specific to tumor
type, but the net result is a cycle of mutual stimulation of host and tumor tissue, leading
to increased tumor growth and aggressive behavior.
Many components and host systems have been identified to play a role in tumor
progression and metastasis, but the interaction between tumor cells and components of
the host hemostatic system plays a particularly important and pervasive role in
metastasis.
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1.1.1 Hemostasis
The human circulatory system has evolved to react to vascular injury in an explosive
manner to prevent excessive blood loss. This rapid response exists in a delicate balance
with tight controls and regulation; initiation of coagulation is followed closely by
activation of fibrinolysis which enables the hemostatic system to stem excessive blood
loss, without giving rise to thrombosis6. An imbalance or defect in any component of the
hemostatic system can lead to a clinical disorder, such as hemophilia upon the loss of
Factor VIII7. The major components and tightly regulated pathways and the interplay
between coagulation, fibrinolysis, and tumor progression will be discussed here.

1.1.2 Vascular endothelium in hemostasis
The vasculature is not just a passive conduit for blood circulation; rather the endothelial
cells lining blood vessels are active participants in hemostasis6. For example, endothelial
cells secrete basement membrane and extracellular matrix (ECM) components such as
collagen, fibronectin (FN), laminin, vitronectin and von Willebrand Factor (VWF), all of
which are pro-thrombotic if allowed to contact blood components6. To protect these
proteins from spontaneous contact with the blood, endothelial cells secrete the antithrombotic molecules thrombomodulin and heparin sulphate on their surface. Upon
stimulation by enzymes like thrombin or under hypoxic or shear stress, leads to tissue
factor (TF) and VWF presentation on their cell surface and alters integrin expression.
This facilitates platelet adhesion and increased FN, collagen and laminin binding. Thus,
the endothelium potentiates a pro-coagulant response. Additionally, damage to the vessel
wall causes blood exposure to sub-endothelial proteins which stimulate formation of
platelet aggregates and thrombi6.

1.1.3 Platelets
Platelets are small (2.5 x 0.5 um) anuclear cytoplasmic bodies which are formed by
fragmentation of megakaryocytes in the bone marrow8. As a major component of the
hemostatic system, 150 - 400 x109 platelets per litre of blood normally circulate within
the human vasculature, but do not adhere to the vascular wall unless stimulated to do so8,
9

. In response to vascular injury, platelets adhere to the exposed sub-endothelium and
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become activated. This activation causes platelets to change from a flat discoid shape to
a more spherical form with extensive pseudopodia and causes the release of proteins from
α-granules8. Activation also causes extensive changes on the platelet membrane with
increased presentation of activated GPIIb/IIIa (αIIbβ3), which allows for binding to
fibrinogen, VWF, FN and vitronectin. Release of fibrinogen from α-granules contributes
to stabilization of the fibrin clot, as αIIbβ3 on the platelet surface mediates binding to
fibrinogen as well as FN and VWF.

1.1.4 Coagulation Cascade
Two separate proteolytic cascades are responsible for initial activation of coagulation –
the intrinsic and extrinsic pathways6. The intrinsic pathway is activated by tissue damage
when blood comes into contact with sub-endothelial tissues. It is responsible for the
initial reaction to tissue damage, but is slower than the extrinsic pathway to activate the
key protease, thrombin. The extrinsic pathway provides a rapid response to coagulation
stimuli and functions mainly to augment the activity of the intrinsic pathway. Both the
intrinsic and extrinsic pathways lead to the common pathway, which results in thrombin
formation after activation of Factor X. The central component to cascade progression
involves binding of the co-factor TF to phospholipid (PL, intrinsic) or Factor VIIa
(extrinsic) to activate Factor IX and Factor X respectively.6 All of the serine proteases
involved in the coagulation cascade circulate as inactive zymogens which prevents
spontaneous clot formation, while still enabling a rapid response to vascular injury.
Figure 1.1 illustrates the progressive nature of the clotting cascade, and outlines the
individual protein-cofactor interactions required. In general, exposure of the
subendothelium triggers the intrinsic cascade leading to pro-thrombin conversion to
activated thrombin6. Thrombin cleaves fibrinogen to the self-polymerizing protein fibrin
to initiate the second phase of clot formation, and also contributes to clot expansion
through increasing activation of Factor VIII, X and XI. Formation of a stable fibrin clot
occurs through thrombin-mediated cleavage of fibrinogen to fibrin, and the subsequent
crosslinking by Factor XIIIa. This fibrin mesh binds platelets together and increases
attachment of the thrombus to the damaged vessel wall and binds to the platelet receptor
IIbβ3. Molecular bridges between fibrin and the plasma proteins FN and

4

Figure 1.1: The coagulation cascade
Vessel wall damage initiates the intrinsic coagulation cascade where each activated
protease is responsible for activating the next. The extrinsic pathway supports and
augments the activity of the intrinsic pathway and leads to increased thrombin activation.
The co-factor TF is essential to the cascade as it is required for activation of thrombin,
the key protease responsible for thrombus formation.
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thrombospondin (TSP), as well as bridging between proteins and platelets, and between
platelets and the vessel wall lead to an increasingly stable clot that is resistant to
dissolution6.

1.1.5 Fibrinolysis
During coagulation, release of tissue type-plasminogen activator (tPA) from the
endothelium converts plasminogen to plasmin and facilitates the initiation of clot
breakdown6. The activity of plasmin is mitigated by its interaction with -antiplasmin
which is directly crosslinked within the fibrin network and therefore influences the
degree and location of fibrinolysis. The tightly regulated nature of hemostasis is due to
the balance that exists between pro-coagulant and platelet aggregation cues, „restingstate‟ inhibition of coagulation, as well as pro-fibrinolytic and anti-fibrinolytic reactions.
Following the rapid and efficient response to injury the clot is gradually reduced to allow
for wound healing and tissue repair6.

1.1.6 Coagulation and Cancer
First recognized by Trusseau in 186510, it has long been recognized that tumors instigate
changes in the hemostatic system that function to support tumor progression4, 11-14.
Tumor growth is associated with a global hypercoagulable state, platelet abnormalities
and thromboembolism, often leading to patient mortality (reviewed in 15). A definitive
role for components of coagulation in primary tumor growth has not been identified, as
tumor growth is equivalent in fibrinogen-deficient and wild-type animals16, 17. During
metastasis however, coagulation factors play an important role in sustained cell arrest,
tumor cell survival and extravasation16-23.

1.2 The role of host systems during metastasis
1.2.1 Tumor cell invasion and intravasation
Excessive proliferation of neoplastic cells in a developing cancer leads to hypoxia and
necrosis in the tumor microenvironment. Tumor and stromal cells react by secreting
growth factors and cytokines such as colony stimulating factor (CSF)-1 and tumor growth
factor-β (TGF-β), which are chemoattractants for immune cells24. Further host reaction
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to the developing neoplasm leads to recruitment of mesenchymal stem cells, activated
fibroblasts, endothelial precursors, dendritic cells, macrophages, monocytes,
lymphocytes, leukocytes and mast cells25, 26. Initially, it is likely that this recruitment is a
host defense mechanism, but the tumor is able to capitalize on the pro-growth factors and
counteract the growth-inhibitory capabilities of the recruited cells26. It would be
expected that an abundance of immune cells would be beneficial for the host, yet it often
correlates with poor clinical prognosis27, 28.
A major effect of the inflammatory response to tumor development is an increase in
tumor invasiveness. Breast cancer cells cultured in macrophage-conditioned media, or
co-cultured with macrophages, show a significant increase in invasive behavior in vitro29,
30

. The resulting increase in matrix metalloprotease (MMP) activity was found to aid

tumor cell invasion30. These results indicate that tumor cells can capitalize on the host
immune response leading to increased invasiveness and subsequent metastasis.
Tumor-associated macrophages (TAMs) are often the most common immune cell in the
tumor microenvironment and play an essential role in tumor metastasis. Using an in vivo
model of mammary carcinoma, it was found that TAMs are most likely to be found at the
margin of a primary tumor, with decreasing numbers upon imaging deeper into the
tumor31. The few TAMs that were found in the tumor core were associated with blood
vessels and were essential for tumor cell intravasation (Figure 1.2 a). Analysis of murine
and clinical samples found that TAMs may guide breast cancer cells toward blood vessels
through epidermal growth factor (EGF)-CSF-1 signaling, as cancer cells were often
found in contact with perivascular macrophages. The density of these interactions in
clinical samples correlated with the histological grade of the tumor and positively
associated with the risk of distant metastasis formation32. It has also been noted that
macrophages are often present at the site of basement membrane breach and tumor cell
dissemination33.
Neutrophils, lymphocytes and TAMs all express and secrete MMPs, which collectively
can degrade every ECM protein. The association of these immune cells with the invasive
border of a tumor leads to a degradation of the physical barrier that prevents tumor cell
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dissemination. This degradation releases and activates many growth factors (TGFβ,
tumor necrosis factor  (TNF), Fas Ligand, heparin bound-epidermal growth factor and
others) that are normally sequestered in the ECM34, 35. It is understood that a tumor is not
a uniformly organized mass – each tumor cell will have differential access to nutrients,
oxygen and tumor stromal components depending on its individual location36. Direct
imaging of murine mammary tumor growth using a mammary window was able to
visualize individual cells longitudinally and evaluate differences in their behavior
depending on their initial location. It was found that those cells in close proximity to
blood vessels showed increased migration and invasion and were more likely to spread
from the primary tumor to the lung than those cells that did not have immediate access to
the vasculature36.
Immune cells are a key component of tumor stroma, but the most abundant stromal cell is
the carcinoma associated fibroblast (CAF)37 (Figure 1.2 a), which is also associated with
an increase in tumor cell invasion. These fibroblasts have been recruited as normal
fibroblasts and are activated to become myofibroblasts, or have been recruited as bone
marrow derived cells (BMDCs) and differentiate into fibroblasts at the tumor site38.
Using a 3-dimensional (3D) in vitro model of the epidermal/dermal microenvironment, it
was found that invasion of squamous cell carcinoma (SCC) cells always followed a
leading CAF39. This leading fibroblast was able to create a track in the Matrigel matrix
through both protease- and force-mediated remodeling that the SCC cells would follow.
The track was found to be necessary and sufficient for SCC cell invasion as removal of
the fibroblasts after track formation still allowed SCC cells to invade. These SCC cells
have not undergone an epithelial-mesenchymal transition (EMT) and are non-invasive. It
had been questioned how tumors that maintained an epithelial phenotype were able to
intravasate; this work illustrates that those tumor cells that are not inherently invasive are
able to co-opt host cells in order to metastasize39. Components of the host coagulation
system are also involved in regulating tumor cell invasiveness. TF is consistently
upregulated in many human malignancies and is found to contribute to many facets of
tumor aggressiveness40, 41. TF is expressed by tumor cells, often at high levels, but also
by many host cells such as endothelial cells, TAMs and CAFs. The main function of TF
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is to activate thrombin which potentiates clot formation, but thrombin is also essential for
activating protease activated receptor (PAR)-1 and -2. Activation of PAR-1 expressed by
tumor cells leads to increased tumor invasion and metastasis through induction of
proteases and cell adhesion molecules42.

1.2.2 Survival and arrest in the vasculature
The host coagulation system is known to play a significant role in tumor cell arrest and
survival in the vasculature. Tumor cells activate or produce many components of the
coagulation cascade such as thrombin, PAR-1, TF, fibrinogen, VWF, and plateletactivating factor (PAF), leading to a „platelet mimicry‟ phenotype43. The hypoxic tumor
environment increases TF expression by endothelial cells, TAMs and CAFs leading to
thrombin production within the primary tumor. This „pre-treatment‟ with thrombin
increases tumor cell adhesion to platelets and the vascular endothelium following tumor
cell intravasation44.
Through expression of TF, tumor cells are able to exploit the host coagulation system to
increase metastatic efficiency. Within five minutes of metastatic cell arrest in the lung
there is evidence of tumor cell association with platelets and fibrin.23 In an elegant series
of papers, Palumbo et al.16-19, 45 evaluated the interplay between metastatic cells and the
individual components of coagulation. They found that loss of host fibrinogen
significantly decreased lung metastasis formation, yet had no impact on the number of
cells that originally arrested in the lung following experimental metastasis cell injection.
Fibrinogen was essential for sustained adherence of tumor cells in the lung vasculature17.
The role for fibrinogen in cancer progression appears restricted to metastasis however, as
fibrinogen knock-out animals had reduced lung metastasis despite equivalent primary
tumor formation in fibrinogen-null and wild type animals16. Evaluation of metastasis in
animals with activation-resistant platelets (platelets present in normal number, but not
able to be activated by thrombin, adenosine diphosphate, or other coagulation stimuli)
showed a significant decrease in experimental and spontaneous metastasis, again due to
reduced survival or retention in the lung vasculature18. Depletion of circulating natural
killer (NK) immune cells prior to metastatic cell introduction resulted in equivalent
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Figure 1.2: Host-tumor cell interactions during metastasis.
Interaction between metastatic tumor cells and the host environment in early stages of
metastasis. (a) A primary tumor is infiltrated with host-derived macrophages and
fibroblasts that aid in tumor cell invasion and intravasation. Upon arrest in a secondary
site, tumor cells often stimulate formation of a thrombus (b), which provides adhesion
contacts and protection from the host immune system. These arrested cells may undergo
apoptosis due to release of nitric oxide from the vascular endothelium (c) or may
extravasate, often with assistance from a host macrophage (d). Not all metastatic cells
extravasate prior to initiating growth in a secondary organ, and intravascular
micrometastases are found (e), especially in the lung. Extravascular micrometastatic
growths (f) are also common, and often found to be associated with host macrophages.
The site of metastatic growth is dependent on many factors, but formation of a premetastatic niche (g) is thought to direct and aid initial growth and survival of metastatic
cells.

(Reprinted from Kirstein JM and Chambers AF. Interactions of Normal Tissues

and Systems with Metastatic Cells: Impact on Location, Survival and Growth. In:
Experimental and Clinical Metastasis: A Comprehensive Review - In Press (Springer))
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metastasis number in platelet mutant, fibrinogen knock-out and wild type animals,
indicating that platelet- and fibrinogen-mediated thrombus formation protects tumor cells
from NK cell surveillance in the lung vasculature18. The role of NK-mediated cell killing
was strengthened through work on Factor XIII, which stabilizes fibrin and other ECM
components through catalysis of crosslinkages6. Factor XIII was found to be essential in
preventing NK cell immunosurveillance of tumor cells45. Crosslinking between tumor
cells and platelets also contributes to firm arrest in the vasculature, as normal platelet
bridging to the vasculature (in response to vasculature damage) assists to tether tumor
cells within the vessel14. Thus, thrombi provide a physical barrier between tumor cells
and circulating immune cells, and may actually lead to suppression of the immune
response as TGFβ from platelets has been found to decrease the immunostimulatory
factor interferon γ46.
The formation of a thrombus at the surface of an arrested tumor cell has also been linked
to increased metastasis through maintenance of cell adherence in the pulmonary
vasculature (Figure 1.2 b)4, 23, 47. Metastatic cells protected in a fibrin clot were able to
change from a rounded morphology and spread along the inside of a vessel. Those cells
that showed stable adherence to the lung vasculature were able to form significantly more
lung metastases than those prevented from spreading through treatment with
anticoagulant agents23. In accordance with this, prevention of thrombus formation with
heparin48, 49 or hiruden50 is linked with reduced pulmonary metastasis due to decreased
cell retention in the lung.
Stable adherence of tumor cells to the vasculature upon arrest appears to be a major
determinant of metastatic efficiency. Comparison of metastatic and non-metastatic cells
injected into the circulation showed no difference in the original number of cells that
arrested in the lung, however only those cell lines that had a metastatic phenotype were
able to resist apoptosis and form micrometastases in the lung51. Tumor cell arrest is also
influenced by host expression of P-selectin. Platelets isolated from P-selectin knock-out
mice were unable to bind to tumor cells in vitro, and experimental metastasis assays
found that there was a decrease in the initial seeding of the lung tissue in P-selectin-null
animals47. Additionally, P-selectin was found to facilitate tumor cell tethering and rolling
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along the pulmonary vasculature, but further binding by IIbβ3 was required to stabilize
tumor cell adhesion52. Integrin 3β1 is also involved in tumor cell adhesion to the
vascular endothelium through sections of exposed basement membrane. Adhesion and
migration of tumor cells was also stimulated by binding of TF on tumor cells to tissue
factor pathway inhibitor -1 (TFPI-1) on tumor associated vessels53. Tumor cellassociated thrombus formation may also increase metastatic cell survival in the
vasculature, as activation of PAR-1 by thrombin leads to transmission of survival signals
and prevention of apoptosis54. Additionally, many growth and survival factors are
released from platelets upon activation and are therefore present within thrombi55.
Tumor cells are able to bind to the provisional matrix provided by a fibrin clot thereby
increasing metastasis (Figure 1.2 b)16, 56, 57. Further, plasmin-mediated clot dissolution
may aid tumor cells with the next step in metastasis – extravasation from the host
vasculature.

1.2.3 Extravasation and growth initiation in secondary tissue
Compared with the other steps in metastasis, relatively little is known about tumor cell
extravasation at a secondary site. Using cell accounting techniques Luzzi, et al.58 found
that the majority of B16F1 murine melanoma cells had extravasated from the liver
vasculature within 3 days of cell injection58. Importantly, very few of these cells went on
to form micrometastases (2%) and even fewer were able to form macrometastases
(0.02%). Two weeks following tumor cell injection, over one-third of injected cells
remained in the liver as solitary, extravasated cells and 95% of those identifiable cells
were not apoptotic or proliferating (as determined by histological staining for TUNEL
and Ki67). The low rate of metastasis yet high level of extravasation in this model
indicates that in the liver, extravasation may not be an essential part of metastatic
inefficiency. Additionally, using the chick chorioallantoic membrane (CAM), Koop, S et
al.59 found that nearly all B16F1 cells were able to survive and extravasate following
arrest. Tissue inhibitor of metalloproteinases-1-overexpressing B16F1 cells were poorly
metastatic, and yet they were still able to successfully extravasate in the chick CAM
model59. Using ras-transformed and control fibroblasts, it was also found that
extravasation was independent of metastatic ability60. Nearly all ras-transformed
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fibroblasts and control fibroblasts (89 and 96%, respectively) had extravasated from the
chick CAM within 24 hours of initial injection. Additionally, migration of both cell types
within the mesenchymal layer was equivalent, despite having differential invasion
capabilities in vitro60.
Direct visualization of tumor cell extravasation was performed recently in a murine
model of brain metastasis61. Using a cranial window, single cancer cells were visualized
throughout arrest and extravasation. MDA-MD-435 cells were found to arrest in
microvessel branch points and extravasate as single cells. These cells began to proliferate
only after successful extravasation and only when extravasated cells maintained contact
with an abluminal endothelial cell of a brain capillary61.
Study of metastasis to the lung vasculature shows a distinct difference from that seen in
the liver and chick CAM, however. Using the 4T1 murine mammary carcinoma cell line
it was found that these cells arrest in the lung as individuals attached to the vascular
endothelium. The cells were able to form small colonies within three weeks, some
entirely maintained within the vasculature. The colonies were then able to extravasate as
micro or macrometastases62. Further to this, fewer than 2% of HT1080 cells had
extravasated from the lung vasculature within 24 hours of tumor cell injection, and were
found to form colonies within the lung vasculature within three days. These colonies
showed tumor cells that projected outwards from the central focus as „strings‟ following
within the capillaries (Figure 1.2 e)63. Analysis of experimental metastasis of B16F10
melanoma cells in the mouse lung found that the majority of injected cells had
extravasated, with no identifiable clusters or single cells within the pulmonary
vasculature within 4 days of injection64. Using an orthotopic prostate cancer model,
however, the majority of metastatic tumor cells and tumor cell clusters were found within
the vasculature of both the liver and the lung65. Taken together, these data indicate that
the role of extravasation in successful metastasis formation may be specific to the model,
cell type and secondary organ of study.
It is known that arrest of tumor cells is associated with the formation of a fibrin clot at the
arrested cell site. These clots do not persist indefinitely – clot dissolution is mediated by
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the powerful protease plasmin56. This clot breakdown may aid tumor cell extravasation
through activation of MMPs and other proteases. Additionally, activated platelets are
able to increase vascular permeability; platelet secretions and clot dissolution can both
result in retraction of the endothelium to assist immune cell colonization at inflammatory
sites, but during metastasis may enable tumor cell extravasation21. Tumor cells that
express high amounts of urokinase type plasminogen activator (uPA) tend to be more
aggressive and metastatic (reviewed in 66). Clinically, high levels of uPA, uPA receptor
(uPAR), plasminogen activator inhibitor (PAI)-1 and PAI-2 are linked to poor prognosis
and increased metastasis development67, 68.

1.2.3.1

Pre-metastatic niche formation

The site of metastatic cell arrest and growth has been debated for some time – from
Stephen Paget‟s theory of „seed and soil‟ where the tumor cell (seed) must arrest in a
permissible secondary tissue (soil) in order to develop into a tumor2, 69. This century-old
theory still has merit as metastatic cells grow in different tissues depending on the tumor
type they originated from. A type of hospitable „soil‟ has been identified as a premetastatic niche. These regions of secondary tissue show recruitment of clusters of
BMDCs and hematapoietic progenitor cells (HPCs) colonizing a distant organ prior to the
arrival of tumor cells. The primary tumor stimulates pre-metastatic niche formation
through secretion of vascular endothelial growth factor (VEGF) and placental growth
factor (PlGF), which recruit VEGF receptor 1 (VEGFR1)-positive cells. PlGF in
particular increases the proliferation of fibroblast-like cells and stimulates their
production of FN70. BMDCs expressing VEGFR1 and 4β1 integrin arrest in regions of
increased FN synthesis and secrete MMP-9 which may degrade the basement membrane
to allow extravasation of more BMDCs and/or metastatic cells. They are also found to
express Id3, which is involved in proliferation and mobilization of HPCs from the bone
marrow and maintains an activated state within the BMDC clusters. These clusters alter
the local microenvironment and activate integrins and chemokines such as stromal
derived factor-1 (SDF-1). This activation leads to further recruitment of BMDCs and
increased attachment, survival, and growth of tumor cells (Figure 1.2 g)71. Pre-metastatic
niche formation can also be directed by platelet aggregation72. At a site of endothelium
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disruption, platelet activation was essential for recruitment of BMDCs, which adhere to
P-selectin and IIbβ3 on the platelet surface, rather than to exposed ECM73. Additionally,
SDF-1 released from platelets leads to ongoing retention of BMDC and tumor cell
arrest73.
Interestingly, the location of pre-metastatic niche formation was found to be driven by
factors released from the primary tumor, with different tumor types stimulating niche
formation in differing locations. Injection of conditioned media from one tumor type was
able to confer its metastatic pattern onto another tumor type71. The specific factors
involved in this stimulation have not been fully elucidated, but intriguing work with
human breast cancer cells has identified osteopontin as a major player74.

1.2.3.2

Osteopontin

Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein that is involved
in many cellular functions including adhesion, invasion, migration, and prevention of
apoptosis (reviewed in 75, 76). Analysis of patient plasma has found that high OPN levels
correlate with poor prognosis in breast,77 prostate,78 lung79, 80 and ovarian81 carcinomas.
Additionally, overexpression of OPN has been detected in melanoma, stomach and
colorectal cancers (reviewed in 82). OPN expression by tumor cells increases malignant
behaviour and extensive work has been done on the role of OPN and metastasis,
particularly in breast cancer models (reviewed in 76). OPN has been found to increase
spontaneous pulmonary and lymphatic metastasis83 and the effect of OPN has been linked
to β3 integrin-mediated signalling84. OPN has also been linked to increased tumor
angiogenesis and plays an important role in immune and inflammatory responses85.
Investigation of the role of the tumor microenvironment on tumor progression identified
OPN as a protein involved in BMDC mobilization thereby increasing tumor
development. McAllister, SS et al.74 investigated the effect of an actively growing
primary tumor on the growth of an otherwise indolent tumor on the contralateral side. It
was found that OPN expression from the growing tumor stimulated BMDC mobilization
and colonization of both tumor sites, leading to increased growth and progression74.
This effect of a primary tumor indicates that the full interaction between a tumor and host

15

is exceptionally complex and involves the interaction between primary tumor, host
systems, and metastatic cells.

1.2.4 Angiogenesis and sustained growth
Sustained primary tumor and metastatic growth beyond ~1mm3 requires the recruitment
of a blood supply86. Vascularization of tumors promotes growth by providing oxygen
and nutrients and increases metastasis by providing an entry point into the circulation.
Normal tissues undergo angiogenesis during development, wound healing and tissue
regeneration, through a tightly regulated system leading to structured, hierarchical
branching of vessels87. This regulation is due to coordinated expression levels of proand anti-angiogenic factors, and is lost during tumor neo-vascularization. Deregulated
angiogenesis in a tumor is due to an imbalance between pro- and anti-angiogenic factors
in the tumor microenvironment. The over-expression of pro-angiogenic factors VEGF-A,
angiopoietin (Ang)-2, basic fibroblast growth factor and TGFβ leads to constant
stimulation of angiogenesis and a reduction in stabilized vessels. This leads to poor
tissue perfusion, high vasculature permeability and chronic inflammation and an increase
in metastasis due to ease of metastatic cell entry into the vasculature88. Thus, the tumor
vasculature is characterized by highly tortuous dysfunctional vessels due to improper
regulation of angiogenesis89.
Expression of VEGF-A by tumor cells, macrophages90-92, neutrophils93, platelets94,
fibroblasts95 and endothelial cells96 tips the balance of pro- and anti-angiogenic factors in
the tumor microenvironment and leads to widespread activation of angiogenesis. VEGFA is elevated in response to hypoxia and inflammation, which are common in during
tumor formation. Solid tumors tend to have a hypoxic core due to poorly functioning
vasculature leading to constant stimulation of pro-angiogenic factors such as VEGF-A97.
The process of angiogenesis in the metastatic setting is thought to proceed through
similar mechanisms as seen in the primary tumor. Initial growth of a micrometastasis is
halted without the recruitment of a blood supply, leading to a functionally dormant
metastasis with balanced levels of proliferation and apoptosis98. Upon activation of the
„angiogenic switch‟99 tumor cells and macrophages present at the metastatic site stimulate
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expression of VEGF-A leading to the same cascade of angiogenic events as seen in the
primary tumor setting98.
Blood clot formation at the metastatic site provides further angiogenic and growth signals
as platelet activation results in the release of many growth and pro-angiogenic factors
such as VEGF, platelet derived growth factor (PDGF), Ang-1, TGFβ, insulin-like growth
factor 1, EGF, and platelet-derived epidermal growth factor (PD-EGF). Additionally,
thrombin activity is linked to increased angiogenesis through up-regulation of cathepsinD which increases endothelial cell growth, migration and tube formation in vitro100.
Thrombin may also play an important role in angiogenesis through induction of VEGF-A
in tumor cells101 and platelets102, as well as Ang-1 and -2 from platelets103 and endothelial
cells101 respectively.

1.2.5 Host-tumor interactions as therapeutic targets
As described above, there is extensive interaction between the primary tumor, the host
and developing metastases. There is the potential for the tumor to exploit host systems
and augment tumor progression; yet therapeutic interventions to prevent this exploitation
have not been well investigated. Full understanding of the complex relationship that
exists between tumor, host, and metastases is required to allow development of new types
of host-defence therapeutics. An example of treating the host to treat the tumor lies in
clinical modulation of hemostatic targets. Given the robust interaction between
metastatic cells and the host hemostatic system16-23 it is not surprising that treatment of
patients with anti-coagulants has a role in metastatic progression. Of great clinical
interest is the role of P-Selectin inhibition on tumor progression as murine models of
metastasis have shown that treatment with several types of low molecular weight heparin
(LMWH) leads to inhibition of metastasis through binding to P-Selectin and preventing
platelet adhesion to tumor cells (reviewed in 55). Several other pharmacologic means of
inhibiting tumor cell interaction with coagulation factors include antibody-mediated
inhibition of integrin function, specific inhibition of thrombin, targeting of PARs, and
inhibiting platelet aggregation, though the anticancer efficacy of antiplatelet agents has
not been tested in clinical trials (reviewed in 104).
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1.3 Pharmacologic modulation of hemostasis
Modulation of hemostasis through pharmacologic intervention enables treatment of many
clinical concerns, such as deep vein thromboses and pulmonary embolism105. Treatment
of patients with venous thromboembolism (VTE) with anti-coagulants can significantly
reduce the risk of stroke and myocardial infarction and their associated morbidity and
mortality. All anti-coagulants carry the risk of excessive bleeding and treatment must be
monitored closely105. Alternatively, major surgical intervention (cardiopulmonary
bypass, liver resection, hip replacement, others) has the concern of excessive blood loss
during surgery106. Treatment of surgical patients with anti-fibrinolytic agents has been
shown to significantly reduce the number of blood transfusions needed during surgery as
well as the need for re-operation to control bleeding107. The mechanism of action of anticoagulant and anti-fibrinolytic agents, their clinical use, and their role in cancer is
discussed below.

1.3.1 Heparin and anti-coagulant therapies
Heparin molecules are long, unbranched polymers of glucosamine and galacturonic acid
and are highly heterogeneous in length105. The molecular weight of unfractionated
heparin (UFH) ranges from 3000 to 30,000 daltons, but only a third of heparin molecules
have the high-affinity pentasaccharide required for anti-coagulant activity105. Heparin
drastically inhibits thrombin activity by binding to antithrombin (AT) and increasing its
affinity for thrombin and factor Xa. Long-chain heparin molecules can also directly bind
and inhibit thrombin activity. Low molecular weight heparin (LMWH) is derived from
heparin through enzymatic or chemical depolymerisation and has a smaller and more
narrow size range (1000 – 10,000 Da)105. The major difference between UFH and
LMWH is reduced interaction between LMWH and thrombin, but LMWH maintains its
anti-coagulant activity through interaction with AT. LMWH has several advantages over
UFH, including an extended half-life and more predictable anti-thrombotic dose
response108. Recent clinical studies of UFH and LMWH treatment of VTE in cancer
patients has identified a significant increase in survival following extended treatment108,
especially with LMWH. Importantly, this effect may be in-part due to mechanisms
outside of anti-coagulation108, 109.
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1.3.2 Anti-coagulants and cancer
Cancer patients are prone to development of VTE, leading to significant morbidity and
mortality15, 110-112. The hypercoagulable state in cancer patients is due to a number of
factors including i) alterations in blood flow due to patient immobility, tumor-induced
mechanical blockage, or thrombocytosis; ii) impaired vessel integrity due to extensive
angiogenesis, tumor cell-induced vascular damage (during invasion and metastasis) or
poorly functional, leaky tumor vasculature; iii) procoagulant activity of tumor cells14, 15,
41, 110-114

. Treatment of cancer patients with anticoagulants for relief of VTE has led to

the important discovery that LMWH therapy can improve patient survival, especially in
those patients who did not have identified metastatic disease at the time of study
enrolment115. Interestingly, this survival benefit may not be due to prevention of
coagulation, as treatment with the non-heparinoid anti-coagulant coumarin did not lead to
a similar survival benefit116, 117.
Indeed, inhibition of coagulation is able to decrease metastasis as treatment with the
thrombin-specific inhibitor hiruden leads to a significant inhibition of experimental lung
metastasis50. Heparin has been definitively shown to alter early events in metastasis,
specifically the sustained arrest and survival of tumor cells in a secondary capillary bed23,
49

. Inhibition of fibrin and platelet deposition around tumor cells leaves them vulnerable

to NK-cell mediated killing18, 19, but the multi-faceted role of heparin in vivo indicates
that non-anticoagulant mechanisms may also play a role in heparin-mediated reduction of
metastasis. For example, heparin can block P- and L-Selectin, which has been shown to
reduce sustained metastatic cell arrest117. Heparin also affects the activity of growth
factors, causes the release of TFPI, inhibits angiogenesis, alters integrin interactions, and
modulates protease activity112, 118. Thus, the effect of heparin on tumor progression is
multi-faceted and has led to specific pre-clinical investigation of the effect of LMWHs on
metastasis to isolate the effect of individual heparin preparations. The LMWHs
tinzaparin, dalteparin, nadroparin and, enoxaparin have potent anti-metastatic effects
when administered prior to tumor cell delivery (reviewed in 119). Also, derivation of a
LMWH with no anticoagulant ability was still able to protect against experimental
metastasis of B16F10 melanoma cells109. Together, these data indicate the inhibition of
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coagulation can lead to significant inhibition of metastasis, but the effect of the widelyused anti-coagulant heparin may have a multitude of mechanisms as compared to
thrombin-specific inhibitors.

1.3.3 Aprotinin and anti-fibrinolytic therapies
Aprotinin is a broad-spectrum serine protease inhibitor used clinically for several decades
to reduce intra-operative blood loss120. It binds to and inhibits trypsin-like enzymes such
as trypsin, chymotrypsin, plasmin, kallikrein, elastase, and plasmin activator, with
decreasing affinity121. It is the inhibition of plasmin-mediated dissolution of thrombi that
is thought to lead to reduced blood loss122, but aprotinin also demonstrates antiinflammatory and platelet preserving effects123 making it an ideal therapeutic during
invasive surgery. Recently, however adverse clinical reactions following aprotinin
treatment have been identified. A clinical study of 781 patients who received aprotinin
as compared to the lysine analogues tranexamic acid (TXA) and ε-amino caprioic acid
(EACA) found to a slight increase in mortality (6.0% in aprotinin treated vs. 3.9 and
4.0% in TXA and EACA treated respectively) within 30 days of surgery 124. This finding
is controversial as robust meta-analysis of 52 clinical studies (over 7000 patients) found
no such increase107. Despite this disparity, aprotinin has been removed from the clinic
and other anti-fibrinolytic agents such as EACA and TXA have received more
widespread use. The lysine analogue EACA and TXA are more selective protease
inhibitors and are not as effective at reducing surgical blood loss during cardiac surgery
as aprotinin107, 125. Additionally, investigation of inducible nitric oxide synthase (NOS)
expression from bronchial epithelial cells found that EACA126 and TXA127 was not as
effective as aprotinin at reducing nitric oxide (NO) release, indicating that aprotinin
exhibits other clinically-relevant organ protecting effects that may not be present
following treatment with other anti-fibrinolytic agents123, 128-131.

1.3.4 Anti-fibrinolytics and cancer
Routine treatment of patients undergoing invasive surgery with anti-fibrinolytics has led
to investigation of the effect of these agents following cancer-related surgery132. Similar
to the observed effect following cardiac surgery, aprotinin treatment reduced perioperative blood loss in meningioma, femoral osteosarcoma and bladder carcinoma
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surgery133 as well as following liver resection for treatment of colorectal metastases134.
Aside from the significant effect on blood loss during surgery, the role of protease
inhibition by anti-fibrionlytic agents on the tumor cell biology has also been investigated.
Two distinct hypotheses exist for the potential effect of protease inhibition on tumors and
metastatic spread. The first indicates that due to the extensive role of proteases in
angiogeneisis and growth factor activation as well as tumor cell invasion and
extravasation, inhibition of proteases should decrease metastasis by preventing these
essential processes. Alternatively, inhibition of plasmin-mediated clot dissolution could
promote cancer cell survival and metastasis by stabilizing the interaction between
intravascular tumor cells and thrombi23, 135, as illustrated in Figure 1.3. Indeed preclinical data can be found to support both hypotheses. The role of aprotinin on clinical
cancer progression has also been investigated. Treatment of patients undergoing liver
resection for treatment of colorectal metastasis showed a significant increase in patient
survival one year following surgery, but this improvement was not evident 5 years
following surgery as survival rates were then equivalent in aprotinin- and placebo-treated
patients132.

1.3.5 Summary: modulation of hemostasis in cancer patients
Therapeutic modulation of hemostasis in cancer patients is complex and must be closely
monitored, especially given the volatile host background. Importantly, treatment of a
hemostatic imbalance may have effects beyond coagulation and fibrinolysis and may lead
to promotion or inhibition of tumor progression. Detailed understanding of the interplay
between tumors and host systems will allow for more effective treatment options and
ensure that treatment of one facet of disease does not aggravate or promote another.
Related to this approach to cancer research is investigation into the ability of a host to
prevent or restrict tumor progression in order to identify potential targets that could
augment this host response. Specifically, analysis of molecular interactions between
tumor and host or understanding the phenomenon known as concomitant tumor
resistance, where the presence of a primary tumor can restrict the growth of secondary
tumors or metastases, could lead to a promising new generation of treatment options.
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Figure 1.3 Interaction between an arrested tumor cell and cell-surface thrombus.
An arrested tumor cell may stimulate the formation of a thrombus through expression of
TF on the cell surface. Clot formation is normally balanced with fibrinolysis by plasmin,
however in the presence of the serine protease inhibitor aprotinin, fibrinolysis may be
delayed, leading to prolonged interaction between tumor cells and thrombi.
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1.4 Host-mediated inhibition of metastasis
Successful metastasis formation results when tumor cells are able to exploit and avoid
natural host defenses. Yet metastasis is an exceptionally inefficient process2, indicating
that the host is capable of preventing progression of the majority of metastatic cells. The
mechanisms behind this prevention are largely unknown, yet several interesting examples
of host triumph over tumor have been established.

1.4.1 Molecular interactions limiting tumor metastasis
Following tumor cell arrest in the liver vasculature, NO is released and induces apoptosis
in B16F1 cells136. B16F1 cell arrest in the pulmonary vasculature was also found to lead
to an endogenous NOS-dependent release of NO. NO may represent a natural host
defense mechanism as it triggers apoptosis in melanoma cells and reduced the growth of
metastatic tumors (Figure 1.2 c)137. Accordingly, comparison of metastatic and nonmetastatic melanoma cells following arrest in the murine lung showed that non-metastatic
cells were unable to survive in the pulmonary vasculature. Within 8 hours of tumor cell
injection, non-metastatic cells had apoptosed and were cleared from the lung, whereas
metastatic cells persisted and were able to form metastatic colonies within 7 days51.
Given the extensive interaction between tumors and the host, there is the potential to alter
the microenvironment to create an anti-tumor rather than pro-tumor interface. It has been
proposed that the large number of TAMs present in tumor stroma could be „re-educated‟
to target tumor cells138. Using nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-B) signaling, tumor cells are able to keep TAMs in an immunosuppressive
state. By introducing a dominant negative inhibitor of nuclear factor B kinase  into
bone marrow derived macrophages, TAMs became tumoricidal through release of NO
and through promotion of NK cell-mediated killing138. The extensive interaction between
TAMs and metastatic cells throughout invasion and extravasation as discussed earlier
(section 1.2.6) illustrates the great potential for manipulation of TAM activity to reduce
tumor progression.
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Normal tissue structure and function is maintained through proper ECM adhesion and
tissue polarity. In breast and melanoma tumor development, dysregulation of cell
adhesion represents an initiating step in tumor formation139, 140. Therefore the effect of
re-establishing proper tissue architecture and adhesion in tumor tissues has been
investigated141. It was found that restoration of proper integrin signaling within a 3D
culture setting led to phenotypic reversion of breast cancer cells. Without alterations to
tumor cell genotype, tumor cells were induced to form normal breast structures.
Metastatic breast cancer cells could also be reverted to a non-malignant phenotype in 3D
culture following treatment with anti-integrin antibodies142. The global switch in cellular
behavior as a direct result of modulation of environmental interaction indicates the
powerful role that the tumor stroma and microenvironment has on tumor development
and progression and illustrates that many treatment options are available beyond direct
targeting of tumor tissue.

1.4.2 Concomitant tumor resistance
It is a clinically recognized phenomenon that removal of a primary tumor from the patient
can be followed by an explosive outgrowth of previously undetected metastases143. It
appears that the presence of a primary tumor can hold secondary metastases `in check` by
some unknown mechanism which is removed upon excision of the original tumor143, 144.
Indeed, the ability of a primary tumor to restrict the growth of a second tumor implant
was first recognized by Ehrlich in 1906145 and was thought to occur by an immunological
mechanism and was therefore termed concomitant tumor immunity144. The study of
concomitant tumor immunity has led to many significant tangential discoveries that have
improved the understanding of immunology146, angiogenesis147, and tumor growth86, 148.
When first identified, three possible hypotheses were presented that could lead to CTR
(reviewed in 144).
1) Concomitant tumor immunity – the presence of a primary tumor induces an
immunological response against a metastasis or secondary tumor.
2) Production of anti-mitotic or otherwise growth restricting compounds by the
primary tumor that inhibit the development or progression of a second inoculum
or metastasis.
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3) Athrepsia – depletion of essential nutrient or factor by the tumor restricts the
growth of a second tumor mass.
The immune system has been found to play an important role in inhibition or rejection of
a second tumor, but only in highly immunogenic tumor types. The protection afforded by
this immune reaction is tumor type specific – that is the host can only reject the same
tumor cells to which it had been previously exposed, and only if the host had mounted an
immune response upon first exposure144.
Extensive work on concomitant tumor resistance by Judah Folkman‟s group has led to
the current understanding of angiogenesis and the identification of angiogenesis
inhibitors which have since been developed into therapeutic agents86, 147. The underlying
hypothesis for his work was that tumor angiogenesis is based on a balance of pro- and
anti-apoptotic regulators and that if these regulators exit the tumor and enter the serum of
a tumor-bearing host there could be distant effects on other tissues, including secondary
tumors86. Angiostatin, an internal cleavage fragment of plasminogen, was identified and
it was found that it was able to suppress the growth of lewis lung carcinoma (LLC)
metastases due to inhibition of angiogenesis at the metastatic site147. Importantly, tumors
were found to make both pro- (VEGF) and anti-angiogenic factors (TSP, endostatin,
angiostatin) with the local balance tipping toward increased angiogenesis and growth147.
However, differences in stability of pro- and anti-angiogenic factors gives rise to an antiangiogenic environment in regions distant to the primary tumor86.
The third hypothesis, depletion of nutrients is responsible for metastatic inhibition, is
supported by historic literature that found that the Gompertzian growth pattern of primary
tumors occurred simultaneously in distant metastases, despite their significantly smaller
size149. That is, the growth of a tumor slows as the tumor reaches a large size and as the
primary tumor slows the secondary metastases also slow. In the absence of the primary
tumor, these metastases would continue to grow, therefore it was thought that a systemic
depletion of some essential factor led to the communal slowing of all tumors in the
host149. Additionally, many cancer patients150 and pre-clinical models151 show extensive
cachexia – the systemic wasting of the host with weight loss, fatigue, muscle atrophy,
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weakness and a loss of appetite. It is possible that the tumor is usurping nutrients
available to the host leading to the starvation of host tissues and developing metastases151.
Following the identification of anti-angiogenic molecules and understanding of their
ability to restrict the development of secondary tumors, further investigation into the nonimmunogenic mechanisms of concomitant tumor resistance has slowed, despite many
intriguing questions which remain unanswered.

1.5 Conclusions and Rationale
The study of tumor biology and metastasis has long been investigated from the
perspective of the individual tumor cell. However, the importance of tumor cell
interactions with host cells and systems has also been recognized. Tumor cells are unable
to form metastases without interaction with many microenvironments – from the primary
tumor stroma, through the host vasculature and host coagulation systems, to an entirely
new environment in a secondary organ. The metastatic cell‟s ability to survive and
proliferate in each of these new environments depends on its ability to influence and
often exploit the host. Fundamental to this is the interaction of tumor cells with the host
hemostatic system. Understanding the interplay between tumor progression and
hemostasis and the potential for the host to circumvent or prevent metastasis is essential
for understanding metastatic disease. This understanding will provide improved
treatment options through augmentation of beneficial host responses to the tumor and will
improve the chances for and successful patient treatment.
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1.6 Objectives
The complex interplay between a tumor and a host is not fully understood, but it should
be acknowledged that research focusing exclusively on the intrinsic properties of tumor
cells is insufficient. Therefore, the overall objective of this work was to investigate the
interactions between tumor cells and the host and the role that host systems play in
supporting or inhibiting tumor development and progression. To this end, three specific
objectives were undertaken.
1) To investigate the interaction between coagulation and metastatic cells and
determine if global modulation of fibrinolysis would encourage or inhibit
metastasis.
2) To investigate the effect of a murine melanoma primary tumor on secondary
metastasis development and the role of the host coagulation system in this effect.
3) To identify the effect of a breast tumor on metastatic development and to resolve
the conflicting ideas of concomitant tumor resistance and pre-metastatic niche
formation in a breast cancer model.
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Chapter 2

2

Effect of anti-fibrinolytic therapy on experimental
melanoma metastasis

2.1 Synopsis
Anti-fibrinolytic agents such as aprotinin and EACA are used clinically to decrease perioperative bleeding. Use of these treatments during cancer-related surgeries has led to
investigation of the effect of fibrinolysis inhibition on cancer cell spread. The ability of
aprotinin to reduce proteolytic activity of proteases required for metastasis suggests that it
could have an anti-metastatic effect in patients undergoing tumor resection. However,
many metastatic cells in the vasculature of a secondary tissue are associated with a microthrombus. The association of tumor cells with thrombi has been shown to increase their
survival; therefore inhibition of plasmin-mediated fibrinolysis might instead increase
metastatic cell survival by enhancing the association between thrombi and tumor cells.
The goal of this work was to determine the effect of anti-fibrinolytic treatment on
experimental metastasis and to establish the role of coagulation factors in this effect. The
metastatic ability of B16F10 melanoma cells was evaluated in vivo following cell or
animal pre-treatment with aprotinin or EACA. Additionally, a novel in vivo technique
was developed, to permit analysis of tumor cell association with thrombi in the lung
microvasculature using confocal microscopy. Aprotinin and EACA treatment of mice
resulted in a significant increase in lung metastasis. Aprotinin treatment increased the
size of thrombi in association with cells arrested in lung capillaries. This study suggests
that clinical use of anti-fibrinolytic agents for cancer-related surgeries could result in
increased metastatic ability of those cells shed immediately prior to and during surgery,
and that this approach thus requires further study.
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2.2 Introduction
Anti-fibriniolytic agents are often used during invasive surgeries to minimize blood loss
and transfusion requirements1. Of these agents, the serine protease inhibitor aprotinin
had been most commonly used and is highly effective at reducing blood loss in patients
undergoing cardiopulmonary bypass2. Aprotinin therapy leads to a significant reduction
in requirement for blood transfusions3, and reduces post-operative inflammation and
platelet exhaustion, previously shown to improve patient survival1, 4. Aprotinin inhibits
most serine proteases, having a weak effect on thrombin activity but a large effect on
trypsin-like enzymes such as kallikrein, plasmin, plasminogen activator and trypsin5. It is
the potent inhibition of plasmin that leads to reduction of surgical blood loss, through
inhibition of plasmin-mediated fibrinolysis4. Recent clinical studies have indicated an
increased risk of mortality and renal failure associated with aprotinin treatment during
cardiac surgery6, 7, leading to a cessation of its clinical use. Other anti-fibrinolytic agents,
such as the lysine analogs EACA and TXA, specifically inhibit plasmin activity through
binding to plasminogen and preventing its conversion to active plasmin enzyme8. EACA
and TXA have also been used clinically and have been compared to aprotinin in clinical
trials to investigate their effect on blood loss during cardiac surgery1. EACA and TXA
have not been associated with an increase in mortality or other major side effects
including myocardial infarction, pulmonary embolism, deep vein thrombosis, or renal
failure, but also are not capable of reducing blood loss to the same extent as aprotinin at
current doses used1. The use of anti-fibrinolytic agents during cancer surgeries has led to
investigation of their role in cancer progression and spread9, 10.
It is well-established that protease activity is required for tumor cells to form distant
metastases11. Proteases are employed when metastatic cells invade through primary
tumor stroma into the host vasculature, and again when tumor cells extravasate and
infiltrate upon arrest in distant tissues12. Serine proteases, including plasmin, play a
pivotal role in metastatic growth as they function to activate MMPs13 and release growth
factors14, thereby propagating tissue remodeling and increased growth – both essential
processes for metastasis. Additionally, serine proteases can stimulate integrin-mediated
binding to ECM proteins and cell-signaling cascades by activation of PAR-2 and uPAR14.
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Therefore, anti-fibrinolytic therapy could theoretically provide substantial benefit to
cancer patients, not only by reducing blood loss during surgery, but also by reducing the
metastatic ability of tumor cells.
In contrast, it is also possible that metastasis could be promoted by the presence of
coagulation factors and thrombi. Metastatic cells may be coated in activated platelets and
fibrin when they arrest in the secondary site, and this coating has been suggested to aid in
cell survival15-17. Additionally, metastatic cells have been shown to adhere to and migrate
along the temporary fibrin matrix in thrombi18, 19. Many cancer types are known to
secrete factors which activate platelets including TF, thrombin, and CP, suggesting that
coagulation may provide a survival benefit to cancer cells19, 20. Activated platelets also
secrete many growth factors, including VEGF, PDGF and platelet derived-endothelial
cell growth factor20-23, which can promote tumor growth and angiogenesis19, 24, 25. In vivo
analysis of metastasis in animals with congenital coagulation disorders indicates that the
host coagulation state significantly impacts metastasis, as animals with a genetic
predisposition to thrombosis show increased lung metastasis, while animals with a FVIII
deficiency akin to human hemophilia show reduced lung metastasis26. Hence, the major
clinical benefit of anti-fibrinolytic therapy may also prolong the duration of cancer cellthrombus interaction, thereby improving metastatic cell survival and increasing the
number of metastases formed.
The use of anti-fibrinolytics in cancer-related surgeries9, 10 has raised the question of
possible the effects of plasmin inhibition on cancer progression and metastasis. It has
been reported that anti-fibrinolytics may cause a significant increase27, 28 or decrease29-31
in metastasis formation in animal models. Importantly, clarification of this issue has
been difficult due to lack of in vivo mechanistic information linking the action of the
anti-fibrinolytic to the metastatic outcome.
Given the divergent literature on aprotinin and metastasis, coupled with the current
clinical use of anti-fibrinolytics in cancer-related surgeries, thorough investigation of the
effect of anti-fibrinolytic agents on metastatic cells is required. Here, we used a wellestablished model of experimental metastasis to determine the effect of aprotinin and

43

EACA treatment on metastasis, and we present the first report to directly examine the
effect of anti-fibrinolytic agents on tumor cell-thrombus association.

2.3 Materials and Methods
2.3.1 Cell culture and transfections
B16F10 murine melanoma cells (American Type Culture Collection, Manassas, VA)
were maintained in -minimal essential media (Invitrogen, Burlington, Canada),
supplemented with 10% fetal bovine serum (Sigma, Mississauga, Canada). The LacZ
expression vector was generated by cloning the LacZ cDNA into the expression plasmid
pcDNA3.1 (Invitrogen). Stable transfections were performed using Lipofectamine 2000
(Invitrogen) per the manufacturer‟s guidelines. For selection of stable transfectants,
hygromycin (Invitrogen) was added to the medium at 1000 g/mL. Colonies were
allowed to develop and then were isolated and grown as clonal populations. Each
population was screened for intensity and uniformity of X-gal staining, and ability to
retain such characteristics in vitro without selective pressure. A single clone, B16F10LacZ, which consistently stained with high intensity and uniformity, was chosen.
B16F10-LacZ was passaged in vitro without selective pressure for 38 days, and
maintained the original staining characteristics. Additionally, this clone was tested in
vivo and was found to have similar ability to form primary tumors and metastases as the
parental B16F10 cell line. Cells were routinely tested and confirmed to be free of
mycoplasma contamination using the Mycoplasma Plus PCR primer set (Stratagene,
Cedar Creek, TX).

2.3.2 In vitro growth assay
To determine the effect of aprotinin treatment on B16F10-LacZ cell growth under
standard, anchorage-dependent, monolayer growth conditions, cells were plated at 5 x 104
cells/60 mm plate. Cells were maintained in regular growth media or growth media
supplemented with 200 KIU/mL aprotinin (Trasylol  Bayer Pharmaceuticals, West
Haven, CT). Media on both control and aprotinin treated plates was refreshed every 48
hours. Every 24 hours for 8 days, triplicate cultures were trypsinized and viable cells
counted using a hemacytometer. Doubling times were estimated during the exponential
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growth phase, according to the equation: D = t*ln2/ln(Ct/Ci), where t is time (hours) Ct is
cell number at time t, and Ci is cell number at initial time of plating.

2.3.3 Experimental metastasis model
For experimental metastasis assays, B16F10-LacZ cells were suspended in cold, sterile
Hanks Balanced Salt Solution (HBSS, Invitrogen). Cells were injected in 100 L via the
lateral tail vein into female C57Bl/6 mice, as described 32, using 5 x 105 cells/mouse and
10-16 mice/group. All mice were 7 - 8 weeks of age at the time of injection and were
cared for in accordance to the Canadian Council on Animal Care, under a protocol
approved by the University of Western Ontario Council on Animal Care.

2.3.4 Quantification of lung metastases
To enable visualization of lung metastases, mice were euthanized at various time points
following cell injection and whole lungs placed in phosphate buffer (0.1 M sodium
phosphate monobasic, 0.1 M sodium phosphate dibasic, pH 7.3), on ice until all lungs
were isolated. Lungs were stained with X-gal (Bioshop, Burlington, Canada) solution as
described 33 to visualize LacZ-expressing cells. The total number of surface-visible
metastases was determined on intact lung lobes using a stereomicroscope.
The number of B16F10-LacZ tumor cell foci present at early time points (1 and 4 hours
following cell injection) was determined by separating individual lung lobes and imaging
on an inverted microscope (Nikon, Canada), using tissue autofluorescence to visualize
boundaries between foci. The number of tumor cell foci, defined as single cells or
clusters of tumor cells with no intersecting normal lung tissue, was quantified in fifty
random fields per lung by a blinded observer.

2.3.5 Drug treatment protocols
To determine the effect of anti-fibrinolytic treatment on metastasis, animals were pretreated with 5000 KIU aprotinin, 60 mg EACA, or saline (vehicle) fifteen minutes prior
to cell injection. To determine the effect of anti-coagulant therapy on metastasis, animals
were pre-treated with 100 U UFH (Pharmaceutical Partners of Canada), fifteen minutes
prior to cell injection. All treatments were intravenously injected in 100 l volume.
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For cell pre-treatment experiments, B16F10-LacZ cells were pre-treated in culture using
a protocol adapted from Esumi, et al. 34. Briefly, 70-80% confluent dishes were
incubated with standard growth media or media containing 200 KIU/mL aprotinin at
37C for 30 minutes. Cells were washed twice with control growth media at room
temperature and prepared for injection.

2.3.6 Analysis of coagulation using confocal microscopy
To enable analysis of coagulation in vivo, the following confocal microscopy procedure
was developed. B16F10-LacZ cells were labeled in vitro using 5chloromethylfluorescein diacetate, Cell Tracker Green (CMFDA, Molecular Probes,
Burlington, Ontario, Canada), according to the manufacturer‟s instructions. Ten minutes
before cell injection, animals received intravenous injection of 0.12 mg AlexaFluor647conjugated fibrinogen (Molecular Probes) in 80l sodium bicarbonate, pH 8.3. At
various time points following cell injection, animals were euthanized by an
intraperitoneal injection of xylazine/ketamine (5.2 mg ketamine and 0.26 mg xylazine per
20 g body mass). The lung was cleared of blood by gravity perfusion of HBSS through
the right ventricle of the heart. „Flow through‟ perfusate left the body via a puncture
made in the left atrium. Lungs were perfused for 2 minutes, excised and frozen at –80C
to allow for later analysis by confocal microscopy. To visualize, lungs were thawed in
cold HBSS prior to transfer to 0.1% paraphenylenediamine in HBSS for 10 minutes.
Lungs were assessed using a Zeiss LSM 410 confocal microscope, and Carl Zeiss LSM
3.99 software. The presence of tumor cells was determined using green fluorescence and
the focal plane containing the largest volume of the tumor cell was identified. At that
same focal plane, the lung then was scanned for red fluorescence to identify thrombi.
The green and red fluorescence were quantified in pixels by a blinded observer using
ImageJ 35, and the ratio of thrombus to tumor cell area was determined.

2.3.7 Histology
After X-gal staining and transfer to 10% neutral buffered formalin, lung samples were
paraffin embedded, sectioned, and stained with hematoxylin and eosin (H&E). Tumor
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cell-associated thrombi were quantified on 5 H&E stained sections through all five lobes
of the lung from each animal. Counts were performed by a blinded, trained observer.

2.4 Results
2.4.1 Aprotinin treatment increased experimental lung metastasis
To determine the overall effect of aprotinin treatment on experimental lung metastasis,
animals were treated with aprotinin or saline prior to intravenous injection of B16F10LacZ cells. Fourteen days following cell injection, the total number of lung surface
metastases was quantified. Aprotinin treated animals showed a significant increase in the
number of B16F10-LacZ lung metastases (t-test, p < 0.05, Figure 2.1 a).

2.4.2 B16F10-LacZ cell growth is not directly affected by aprotinin
Given that the tumor cells would encounter aprotinin immediately upon administration
into the lateral tail vein, it was unclear if the increase in experimental metastasis caused
by aprotinin is cell autonomous, or if the effect is mediated by the host. Therefore,
B16F10-LacZ cells were exposed to aprotinin in vitro and assessed for changes in growth
characteristics. No change in in vitro growth patterns (lag phase, exponential growth
initiation) was observed (data not shown), and no change in doubling time was found
(Figure 2.1 b).
To determine if the effect of aprotinin was cell-autonomous, yet only evident after in vivo
injection, cells were pre-treated with aprotinin or control media in vitro prior to their
preparation for in vivo injection. No effect of pre-treatment with aprotinin on B16F10LacZ cells was observed, as cells pre-treated in vitro with aprotinin or control media had
equivalent numbers of lung surface metastases 14 days following cell injection (Figure
2.1 c).
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Figure 2.1 In vivo aprotinin treatment significantly
increased the number of lung surface metastases.
a) Animals pretreated with saline or aprotinin
received B16F10-LacZ cells via the lateral tail vein (n
= 16/group) and the total number of lung metastases
was quantified 14 days following cell injection (t-test,
p < 0.05). Aprotinin treatment of B16F10-LacZ cells
in vitro did not impact in vitro or in vivo growth. b) In
vitro doubling time of B16F10-LacZ cells in standard
growth medium supplemented with saline or
aprotinin. Aprotinin treatment did not affect the
growth rate in 2-D culture (t-test, p > 0.05). c)
Number of lung surface metastases from mice
injected with B16F10-LacZ cells that had been treated
with saline aprotinin prior to their preparation for
injection. Aprotinin treatment of cells alone did not
impact the number of resultant lung surface
metastases (t-test, p > 0.05). Columns, mean; bars,
SE.
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2.4.3 Aprotinin treatment increases persistence of cell foci at early
time points
To clarify the mechanism by which aprotinin increased the number of B16F10-LacZ lung
metastases, animals were treated with aprotinin or saline prior to tumor cell injection, and
were sacrificed 1 or 4 hours following tumor cell injection. The mean number of surfacevisible tumor cell foci per mm2 was quantified following X-gal staining of whole lung
tissue. It is known that fibrinogen is a key determinant of stable cell adhesion in the
lung18 and that the number of B16F10 tumor cells remaining in the lung decreases over
early time points (1 hour through 24 hours)36, therefore it was of interest to determine the
effect of aprotinin on early cell survival or retention in the lung. One hour following
tumor cell injection there was no difference in the number of LacZ-expressing tumor
cells or cell foci in control or aprotinin treated animals, indicating that aprotinin did not
affect initial arrest of B16F10-LacZ cells. However, four hours following tumor cell
injection, significantly more B16F10-LacZ tumor cell foci remained in aprotinin-treated
animals (t-test, p < 0.001, Figure 2.2 a and b). Examination of micrometastases revealed
that aprotinin did not affect the growth of surviving tumor cells, as the size of individual
micrometastases was unaltered by aprotinin treatment (Figure 2.2 c and d).

2.4.4 Histological analysis of thrombi associated with B16F10-LacZ
cells
Tumor cell survival is known to be increased in the presence of a micro-thrombus17, and
given the potent inhibition of plasmin-mediated fibrinolysis by aprotinin, the effect of
aprotinin on association of thrombi with B16F10-LacZ cells was investigated. To
determine the effect of aprotinin on the presence of tumor cell-associated thrombi,
animals were treated with saline or aprotinin and sacrificed 1 hour following cell
injection. Quantification of histological sections (H&E) of X-gal stained lung tissue
(Figure 2.3 a) showed a 2-fold increase in the number of thrombi found in association
with tumor cells in aprotinin-treated animals (t-test, p < 0.05, Figure 2.3 b). To determine
if the association between B16F10-LacZ cells and thrombi was essential for the
establishment of lung metastases, animals were treated with the anti-coagulant, heparin
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prior to melanoma cell injection. Heparin treatment significantly abrogated metastasis
formation (Control: 365  38.58, Heparin-treated: 1.571  0.9221; n = 7, p < 0.0001).

2.4.5 Analysis of coagulation in lung capillaries using confocal
microscopy
Given the effect of aprotinin on the persistence of tumor cell-associated thrombi in the
lung 1 hour following cell injection, more detailed analysis of this association was
warranted. Histological analysis was capable of identifying large thrombi in association
with cells lodged in relatively large vessels; however, since the majority of lung
metastases are formed from cells initially arresting in the microvasculature36, 37, it is vital
to examine this cell population. These cells are likely associated with micro-thrombi not
readily visible using standard histological techniques and limited random sectioning. To
address this need, we developed a novel technique which allows evaluation of
coagulation around single or small clusters of tumor cells lodged in the lung
microvasculature. Fluorescently labeled fibrinogen was injected prior to tumor cell
injection and tumor cell-induced thrombus formation was quantified using confocal
microscopy. With this procedure, we were able to clearly visualize thrombi in
association with tumor cells at the earliest time point examined, 5 minutes (Figure 2.4 a),
with the maximum thrombus size seen at 4 hours (Figure 2.4 b and c) and a decreased
size at 6 hours (Figure 2.4 d). The presence of thrombi was not due to an accumulation
of labeled fibrinogen from blockage of the capillaries with tumor cells, as injection of
inert microspheres (20 m, Polysciences, Pennsylvania), which also arrest by size
restriction and cause vessel blockage 36, 38, did not initiate accumulation of fluorescence
(Figure 2.4 f). Additionally, treatment of animals with heparin prior to tumor cell
injection abrogated the presence of thrombi in association with tumor cells (Figure 2.4 g),
indicating that the fluorescent fibrin(ogen) visualized is due to activation of the
coagulation cascade and the presence of thrombi. To determine the effect of aprotinin
treatment on thrombus size of individual capillary-arrested tumor cells, we used the same
procedure to visualize fluorescent tumor cells in lungs of control and aprotinin treated
mice using confocal microscopy. The presence and size of thrombi in micro-vessels was
quantified for tumor cells visible on the surface of whole lung lobes isolated 4 hours
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Figure 2.2 Aprotinin treatment increases the number of B16F10-LacZ cell foci at
early time points.
Animals pretreated with saline or aprotinin received B16F10-LacZ cells via the lateral
tail vein were sacrificed at 1 and 4 hours following cell injection (n = 8/group/time point).
a) Aprotinin treatment increased number of tumor cell foci visualized 4 hours following
injection (t-test, p < 0.001). Columns, mean; bars, SE. b) Representative images of LacZ
expressing tumor cell foci in whole lung 1 or 4 hours following cell injection. Aprotinin
treatment did not affect initial growth of metastases. c) Mean area of lung surface
metastases 72 hours following tumor cell injection. Columns, mean; bars, SE. d)
Representative images of LacZ expressing tumor cell foci in whole lung 72 hours
following cell injection. Scale 50 m.
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Figure 2.3 Aprotinin treatment increased association between thrombi and B16F10LacZ cells.
a) Quantification of the number of X-gal stained tumor cells found in association with
thrombi in the lung (t-test, p < 0.05). Animals were pretreated with saline or KIU
aprotinin prior to receiving B16F10-LacZ cells (n = 8/group). Mice were sacrificed 1
hour following cell injection and lungs were stained to identify -galactosidase
expressing cells. H&E sections through all 5 lung lobes were examined to determine the
number of B16F10-LacZ cells in association with thrombi. Columns, mean; bars, SE. b)
Representative H&E sections showing X-gal stained B16F10-LacZ cells (arrows) in
association with thrombi (arrowheads). Scale 20 m.
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following cell injection. A significant increase in the size of thrombi surrounding tumor
cells was identified in the aprotinin-treated animals (t-test, p < 0.005, Figure 2.5). All
tumor cells scanned had an associated thrombus at 4 hours in control and aprotinintreated mice, indicating that aprotinin does not appear to affect initiation of thrombus
formation. However, aprotinin functions to maintain the tumor cell-associated thrombus,
presumably due to inhibition of plasmin-mediated fibrinolysis, resulting in significantly
larger thrombi surrounding the tumor cells 4 hours after cell injection.

2.4.6 Plasmin-specific inhibition increases lung metastasis
The above data support the idea that the aprotinin-mediated increase in lung metastasis is
due to increased association of B16F10-LacZ cells with microthrombi in the lung
vasculature leading to increased survival or retention of tumor cells in the lung. To
determine if the increased association between tumor cells and thrombi is due to
inhibition of plasmin, animals treated with the plasmin-specific inhibitor EACA were
compared to saline- and aprotinin-treated animals. Animals were treated with EACA,
aprotinin or saline prior to tumor cell injection and the number of lung surface metastases
present at 14 days was quantified. Specific inhibition of plasmin by EACA was found to
significantly increase the number of B16F10-LacZ lung surface metastases as compared
to control (t-test, p < 0.05, Figure 2.6). The increase in metastasis following EACA
treatment was equivalent to the increase seen in the aprotinin-treated group (Figure 6),
indicating that the majority of the effect seen with aprotinin is due to plasmin inhibition.
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Figure 2.4 Analysis of the dynamic association between B16F10-LacZ cells and
thrombi using confocal microscopy.
Tumor cells were treated in vitro with CMFDA to provide green fluorescence. Animals
received AlexaFluor647 conjugated fibrinogen prior to injection of fluorescent B16F10LacZ cells to allow incorporation of fluorescent fibrin into thrombi surrounding tumor
cells. Animals were sacrificed at a) 5 minutes b) 2 hours c) 4 hours d) 6 hours and e) 24
hours following cell injection. f) Animals received a bolus injection of 10m inert
fluorescent microspheres instead of tumor cells and were sacrificed and perfused with
HBSS 1 hour later. No association between fluorescent fibrin(ogen) and microspheres
was identified. g) Animals treated with heparin prior to tumor cell injection showed no
association between tumor cells and fluorescent fibrin(ogen). Images are representative
of the mean thrombus to tumor cell ratio at each time point. Scale 20 m.
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Figure 2.5 Aprotinin treatment increased association between B16F10-LacZ cells
and fluorescent thrombi.
a) Quantification of confocal microscopy images taken from saline and aprotinin treated
animals (n = 9/group), (t-test, p < 0.005). Images are expressed as a ratio of red:green, or
amount of thrombus to amount of tumor cell present. Columns, mean; bars, SE.
Representative confocal images taken from (b) control and (c) aprotinin treated animals.
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Figure 2.6 Plasmin-specific inhibition gives an equivalent increase in lung surface
metastases as aprotinin treatment.
a) Animals were treated with EACA, aprotinin or saline prior to injection of B16F10LacZ cells via the lateral tail vein (t-test, p < 0.05). Animals were sacrificed 14 days
following cell injection and the number of lung metastases was quantified. Columns,
mean; bars, SE. Representative images of whole lungs from (b) control (c) aprotinin
treated and (d) EACA treated animals.
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2.5 Discussion
The effect of anti-fibrinolytic agents on metastasis has not been well established to date.
In particular, the study of single tumor cells interacting with thrombi in the
microvasculature has not been examined, likely due to technical limitations. In the
present study, a well-established model of experimental metastasis was used to
investigate the effect of anti-fibrinolytic therapy on metastasis. Lung metastases were
established by direct injection of B16F10-LacZ into the lateral tail vein of syngeneic
mice. This injection route results in pulmonary metastasis, as the first capillary bed cells
encounter from this injection site is the lung36, 37. Treatment of mice with aprotinin or
EACA prior to injection of B16F10 tumor cells mimics the clinical setting in which
patients receive anti-fibrinolytic therapy prior to surgery or tumor resection1. Tumor
manipulation during surgery is thought to release a bolus of tumor cells into the
circulation39, a process which is mimicked by a bolus intravenous injection of cells in the
experimental model. This model allows quantification of early time points following
tumor cell introduction and arrest in the lung.
It was determined that anti-fibrinolytic treatment increased the total number of lung
metastases formed from B16F10-LacZ cells. This increase was not due to a direct effect
on the tumor cells themselves, as in vitro treatment of cells with aprotinin did not affect
their in vitro growth patterns or their metastatic ability in vivo. It is well-established that
B16F10 cells induce local coagulation upon arrest in secondary organs40-43 and this
association has been shown to increase metastatic burden of several types of tumor cells,
including melanoma17, 18, 44, 45. Despite an increase in tumor cell-associated thrombi,
aprotinin did not appear to affect initial cell arrest, as there was no difference in the
number of tumor cell foci in the lung one hour following cell injection. However,
aprotinin increased cell survival or retention in the lung, as significantly more tumor cells
were present in aprotinin-treated animals four hours following cell injection. This
increase may be due to a persistent increase in tumor cell association with thrombi
present in large vessels at 1 hour as determined by histology, and in the microvasculature,
as identified by our technique, leading to increased cell survival at 4 hours.
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To evaluate the effect of aprotinin on thrombus-tumor cell association, a novel and
simple confocal microscopy technique was developed here, to evaluate tumor cellassociated thrombi at early points during metastasis. This novel imaging technique
allowed for the first direct investigation of the effect of anti-fibrinolytic therapy on
individual tumor cell interaction with the microvasculature. Fluorescently labeled
fibrinogen, injected prior to tumor cell delivery, produced clearly visible thrombi in the
microvasculature that was specifically induced by the local presence of tumor cells.
Little or no fluorescent signal was visible in areas devoid of tumor cells, or in areas of
physical microvasculature blockage by inert microspheres. This technique offers
advantages over previously reported techniques utilizing fluorescently labeled antibodies
to fibrinogen or platelets as these techniques may label only the surface of thrombi and
require a specialized chamber to maintain perfusion and ventilation of the lung ex vivo16.
The use of this confocal microscopy technique will facilitate future studies of interactions
of tumor cells with thrombi, and enables investigation of the dynamic interaction of
tumor cells with thrombi, by identifying only those thrombi that have formed following
injection of fluorescent fibrin(ogen). Additionally, the simplicity of this new technique
allows for the study of coagulation in other areas of research such as sepsis,
atherosclerosis, Crohn‟s disease and others, without requiring extensive protocol
development or equipment.
To determine if the increase in metastasis seen in aprotinin-treated animals was due to
reduced clot dissolution caused by inhibition of plasmin, animals were treated with the
plasmin-specific inhibitor EACA. Treatment with aprotinin and EACA gave an
equivalent increase in the total number of lung surface metastases following injection of
B16F10-LacZ cells.
Previous work has shown that aprotinin may potentially inhibit metastasis at several
steps46, 47, including reduction of cell intra- and extravasation, decreased growth factor
activation and inhibition of angiogenesis14. Conversely, the increase in metastasis in
animals with a predisposition to thrombosis indicates that the extended presence of
thrombi may increase metastasis. Additionally, the observed reduction in metastasis
following treatment with the anti-coagulant, heparin indicates that association between
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B16F10-LacZ tumor cells and thrombi is essential for lung metastasis, as has been
observed in other tumor models48-50. This reduction in metastasis following anticoagulant therapy is mimicked in mice with a FVIII deficiency26, indicating that
stabilization of thrombi by anti-fibrinolytic agents may result in an increase in metastasis,
as was identified in this study. Treatment with anti-coagulants has also been shown to
reduce tumor cell adhesion to the vascular endothelium by interfering with tumor cellSelectin binding, and has been found to alter the distribution of tumor cells that have been
directly injected, giving rise to extra-pulmonary metastases following tail vein injection
(reviewed in 48). Additionally, treatment of patients with advanced malignancy with low
molecular weight heparins was found to improve patient survival51, 52, especially in those
patients with a more favorable starting prognosis52.
The interaction between specific cancer cell types and coagulation will have varying
degrees of importance, depending on the degree of coagulation activation. Therefore
metastasis those cancer cells capable of causing extensive coagulation will be affected
more drastically by both anti-coagulant and anti-fibrinolytic agents. This complex
interplay between metastatic cells and the host coagulation system indicates that the
importance of the interaction may be specific to certain tumor cell types and that the
timing of anti-coagulant or anti-fibrinolytic therapies may become important during
cancer treatment, with the majority of the effect of these agents occurring while tumor
cells remain in the vasculature.
Interaction between hemostatic factors during hematogenous metastasis has been known
for many years. Patients with metastatic disease often have complications resulting from
a hyper-coagulable state, including deep vein thrombosis and disseminated intravascular
coagulation53. Many tumor cells activate coagulation upon their arrest in the vasculature
by expressing pro-coagulant molecules such as TF or CP18, 19. The association of tumor
cells with thrombi in the vasculature has been shown to increase the metastatic ability of
tumor cells, by increasing cell spreading along the endothelium16, increasing retention of
tumor cells in the secondary tissue16, 18, 34, 54, and by increasing tumor cell survival17, 54, 55.
Specifically, the interaction of tumor cells with activated platelets is important for
metastasis, as mice lacking platelets or possessing platelets that cannot be activated by
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thrombin both show marked reduction in metastasis41, 54. It has also been demonstrated
that tumor cells and platelets can cooperate to induce increased endothelial cell retraction,
allowing for extravasation of LLC cells56. Additionally, platelets have been proposed to
increase tumor cell proliferation and enhance tumor cell interaction with the extracellular
matrix57.
Fibrin(ogen) is also associated with increased metastasis, as fibrinogen knockout mice
show reduced spontaneous and experimental metastasis of LLC cells17, 54. Circulating
fibrin(ogen) has also been found to be essential for effective colonization of the mouse
lung by preventing lysis of tumor cells by NK immune cells17, 43, 54. This function is
shared by circulating platelets, indicating that thrombus formation leads to a reduction of
NK cell-mediated killing of tumor cells. Given the substantial benefit of micro-thrombi
to tumor cells in the vasculature, stabilization of these thrombi by aprotinin-mediated
inhibition of plasmin activity could significantly increase tumor cell survival.
Following publication of several observational studies that showed an increase in
mortality following aprotinin treatment6, 7, aprotinin is no longer utilized during cardiac
surgery. Instead, the lysine analogs TXA and EACA have begun to be used clinically to
reduce blood loss. A review of clinical data found that the currently used dosing
regimens of TXA and EACA do not provide an equivalent reduction in blood loss as is
seen with aprotinin treatment1. As a suitable alternative to aprotinin to reduce blood loss
during surgery is considered, treatment of patients undergoing cancer-related surgeries
with an anti-fibrinolytic agent requires careful evaluation, given the significant increase
in metastasis observed in the present study following aprotinin and EACA treatment.
With clinical use of aprotinin suspended, this report highlights the need to evaluate novel
anti-fibrinolytic agents to determine their effect on tumor cell induced thrombi and tumor
cell survival prior to their widespread use in the clinical setting. The experimental
metastasis model and the novel method of evaluating tumor cell–thrombus interactions at
the single cell level described in this report will prove invaluable in this regard.
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Chapter 3

3

Primary melanoma tumor inhibits metastasis through
alterations in systemic hemostasis

3.1 Synopsis
Progression from a primary tumor to the formation of distant metastases requires
extensive interactions between individual tumor cells and their microenvironment.
Importantly, the primary tumor is not only the source of metastatic cells shed into the
circulation, but it can also modulate the host response to these cells, leading to an
enhancement or inhibition in metastatic progression. Primary tumor-mediated
stimulation of host bone marrow can result in pre-metastatic niche formation and
increased metastasis, but a primary tumor can also inhibit metastasis through concomitant
tumor resistance – inhibition of tumor growth by existing tumor mass. Herein, the
presence of a B16F10 primary tumor was found to significantly restrict the number and
size of experimental lung metastases through reduction of circulating platelets, which
limited the formation of metastatic tumor cell-associated thrombi. Tumor-bearing mice
displayed splenomegaly that correlated with primary tumor size and platelet count. The
reduction in platelet number in primary tumor-bearing animals was specifically
responsible for metastatic restriction, as restoration of platelet numbers using isolated
murine platelets re-established both tumor cell-associated thrombus formation and
experimental metastasis to levels seen in tumor-naïve animals. The consumption of
platelets due to the presence of a B16F10 primary tumor is thought to be a form of
concomitant tumor resistance and demonstrates the extensive impact a growing tumor
can have on a host beyond the local environment. Understanding the interplay between a
primary tumor and secondary metastases is essential, as further identification of
mechanisms behind concomitant tumor resistance may allow inhibition of metastatic
growth following clinical tumor resection.
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3.2 Introduction
The evolution of metastatic disease from a primary tumor occurs though a series of
essential steps – tumor cell invasion and intravasation, arrest in a distant capillary bed,
extravasation and growth initiation in the secondary organ, and sustained growth with
recruitment of a new vasculature1. Survival of metastatic cells during each of these steps
depends on interaction with and evasion of host responses to both the primary tumor and
metastatic cells2. The interaction between a primary tumor and the development of
distant metastases has long been acknowledged, with clinical evidence of massive
metastatic outgrowth following removal of primary breast and colon carcinomas3-5. The
mechanism behind concomitant tumor resistance, the ability of a primary tumor to restrict
the development of a second tumor6, 7, has not been resolved. Better understanding of
concomitant tumor resistance would allow metastatic inhibition through supplementation
or depletion of factors to mimic the presence of a primary tumor, and thereby continue
secondary tumor growth restriction after primary tumor resection.
Three hypotheses have been proposed to explain the protection from metastatic growth
by a primary tumor: concomitant immunity, whereby a primary tumor may prime the host
immune system and enhance clearance of metastatic cells8; production of inhibitory
factors (anti-mitogenic or anti-angiogenic) from the primary tumor which prevent growth
of the secondary tumors5, 9; and athrepsia, the depletion of required systemic factors by
the primary tumor thereby preventing metastatic establishment (reviewed in 7).
Investigation of concomitant tumor resistance led to the ground-breaking discovery of
angiostatin, an anti-angiogenic factor produced by a primary tumor that is capable of
preventing angiogenesis in secondary tumors10. Concomitant immunity has been found
to occur only in highly immunogenic tumor types, such as those arising following
chemical insult, and only while those tumors remained small (<500 mm3)11, unless
animals were depleted of specific regulatory T cells12. The concept of athrepsia as it
applies to metastatic growth has not been well investigated to date7.
It is well established that coagulation factors are essential to successful metastasis
formation13, especially for B16 murine melanoma cell lines14-16. Our group and others
have shown that elimination of individual coagulation factors restricts pulmonary
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metastasis formation14, 17-20, in part by allowing increased NK immune cell killing of
tumor cells16, 21, 22. Stabilization of cell surface thrombi using the serine protease
inhibitor aprotinin increased metastasis formation due to sustained interaction between
thrombi and metastatic B16F10 cells14. B16F10 cells express TF and are individually
capable of activating the coagulation cascade23. Thus it was hypothesized that cells
within a B16F10 primary tumor may stimulate thrombus formation and may deplete
systemic coagulation factors such as platelets. Platelets have long been hypothesized to
support cancer progression24 and have been definitively linked to increasing formation of
metastases through stabilization of tumor cell arrest and increasing survival in the
vasculature, as well as increasing extravasation and proliferation in secondary tissues.16, 25
Given that tumor cell-associated thrombi are essential for successful metastatic
progression, we hypothesized that the presence of a B16F10 primary tumor would
therefore restrict lung metastasis.
Here we analyzed the effect of a B16F10 primary tumor on metastasis formation. We
found a significant inhibition of lung metastasis formation following a secondary
intravenous injection of B16F10-LacZ cells in primary tumor-bearing mice. This
decrease was due to reduced thrombus formation at the metastatic site (lung) caused by a
significant reduction in circulating platelet numbers. Re-constitution of platelet counts in
tumor bearing mice using isolated murine platelets restored cell surface thrombi and led
to equivalent metastasis formation in tumor-bearing and tumor-naïve mice.

3.3 Materials and Methods
3.3.1 Cell Culture
B16F10 and B16F10-LacZ14 murine melanoma cells (American Type Culture Collection,
Manassas, VA) were maintained in -minimal essential media (Invitrogen, Burlington,
Canada), supplemented with 10% fetal bovine serum (Sigma, Mississauga, Canada) and 1
mg/ml hygromycin (Invitrogen, B16F10-LacZ only). For injection into mice, cells were
trypsinized from 70-80% confluent plates and suspended in cold, sterile Hanks Balanced
Salt Solution (HBSS, Invitrogen) to a final concentration of 5 x 106/mL.
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3.3.2 Experimental Metastasis Model
Female C57Bl/6 mice (6-7 weeks old, Charles River) were lightly anesthetized with
isofluorane and 100 l of the B16F10 cell preparation (primary tumor group) or cell
vehicle (HBSS, tumor-naïve group) was injected orthotopically into the dermis (i.d.) on
the right hind flank. Tumor growth was evaluated by measurement with calipers in two
perpendicular dimensions and the tumor volume was estimated using the following
formula volume = 0.52 (width)2(length), for approximating the volume (mm3) of a
ellipsoid. Primary tumors were allowed to grow for 16 days, at which time B16F10-LacZ
cells were trypsinized from 70-80% confluent plates and suspended in cold, sterile HBSS.
Unanesthetized tumor-bearing and tumor-naïve mice then received an intravenous (i.v.)
injection of 5x105 cells in 100 l HBSS via the lateral tail vein. Animals were sacrificed
6 days following i.v. injection and lung tissue was isolated, stained for β-galactosidase
activity and the number of lung surface metastases quantified.
For platelet restoration studies, 100 µl of the platelet suspension (see 3.3.5 Platelet
isolation and preparation) or vehicle was injected via the lateral tail vein 5 minutes prior
to i.v. B16F10-LacZ cell injection. Animals were sacrificed 6 days following i.v.
injection and lung tissue was isolated, stained for β-galactosidase activity and the number
of lung surface metastases quantified.
All mice were 7 - 8 weeks of age at the time of injection and were cared for in
accordance to the Canadian Council on Animal Care, under a protocol approved by the
University of Western Ontario Council on Animal Care.

3.3.3 Quantification of lung metastases
To enable visualization of lung metastases, mice were euthanized 6-days following i.v.
cell injection and whole lungs placed in phosphate buffer (0.1 M sodium phosphate
monobasic, 0.1 M sodium phosphate dibasic, pH 7.3), on ice. Lungs were stained with
X-gal (Bioshop, Burlington, Canada) solution as described 26 to visualize LacZexpressing cells. The total number of surface-visible metastases was determined on
intact lung lobes using a stereomicroscope. Area of individual lung metastases was
determined using the Axiovert 200M microscope and Axiocam HRC camera utilizing

69

Axiovision 4.6 software. Linear length and width of each metastasis was determined, and
area of each was estimated by assuming an approximately elliptical shape and using the
formula π x length x width/4.

3.3.4 Assessment of circulating platelet numbers
Sixteen days after hind flank injection of cell vehicle or B16F10 cells, tumor-naïve and
B16F10 primary tumor-bearing mice were anesthetized with isoflurane and blood was
drawn by cardiac puncture using a heparinized syringe and collected into purple top
(ethylenediaminetetraacetic acid, EDTA) 2 mL tubes (BD Biosciences, Mississauga,
Canada). The number of platelets was determined on a Coulter LH 780 Hematology
analyzer. The normal platelet count seen in mice is 900 – 1600 x 103 / µl but the number
quantified on clinical hematology analyzers is frequently underestimated due to the
smaller size of murine platelets.27 To ensure this did not skew our data, all
quantifications were performed on the same machine. For platelet re-constitution studies,
mice received an i.v. injection of platelets 5 minutes prior to cardiac puncture and blood
collection as above to determine the number of platelets present when B16F10-LacZ cells
would be delivered.

3.3.5 Platelet isolation and preparation
For platelet re-constitution experiments, blood was obtained from female C57Bl/6 retired
breeders (30 - 35 g) under isofluorane anaesthetic via cardiac puncture using citrated 3
mL syringes. Blood was collected into 2 mL Eppendorf tubes with citrate-dextrose
solution (0.1 M trisodium citrate, 0.11 M dextrose, 71 mM citric acid monohydrate) at
1:9 citrate-dextrose:blood ratio. Platelets were isolated using a differential centrifugation
protocol based on Musaji et al.28. Briefly, whole blood was centrifuged at 220 g for 6
minutes at 4C and platelet rich (PR) upper layer was collected. Cold, buffered saline
glucose citrate (BSGC: 8.6 mM Na2HPO4, 1.6 mM KH2PO4, 0.12 M NaCl, 0.9 mM
EDTA, 13.6 mM NaCitrate, 11.1 mM D-Glucose, pH 7.3) was added to each tube to 1.75
mL and inverted to mix. PR upper layer was collected following another 220 g spin for 6
minutes at 4C. This step was repeated once more. PR suspensions were pooled and
centrifuged at 1613 g for 15 minutes at 4C to pellet platelets. Supernatant was discarded
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and platelets were resuspended in 1 mL cold BSGC. To isolate platelets from other
cellular components, the platelet suspension was centrifuged at 220 g for 6 minutes at
4C and PR suspension was transferred to a clean Eppendorf tube. Platelets were
pelleted at 1613 g for 10 minutes at 4C and supernatant discarded. Platelets were then
resuspended to appropriate volume in BSGC for immediate injection. To confirm that
platelets had not become activated during the isolation procedure, a small aliquot was
removed from the final suspension to be tested. Only after the addition of thrombin did
the platelets clump and the previously cloudy suspension become clear. Animals
received a 100 µl i.v. injection that contained platelets concentrated from 3 or 6 mL of
whole murine blood. Only those vials that showed no evidence of coagulation were used
for platelet isolation.

3.3.6 Analysis of coagulation using confocal microscopy
To enable analysis of coagulation in vivo, confocal microscopy was performed using a
previously developed technique14. B16F10-LacZ cells were labeled in vitro using 5chloromethylfluorescein diacetate, Cell Tracker Green (CMFDA, Molecular Probes,
Burlington, Ontario, Canada), according to the manufacturer‟s instructions. Ten minutes
before cell injection, animals received intravenous injection of 0.12 mg AlexaFluor647conjugated fibrinogen (Molecular Probes) in 80 µl sodium bicarbonate, pH 8.3. Fourhours following cell injection, animals were euthanized by an intraperitoneal injection of
xylazine/ketamine (5.2 mg ketamine and 0.26 mg xylazine per 20 g body mass). The
lung was cleared of blood by gravity perfusion of HBSS through the right ventricle of the
heart. „Flow through‟ perfusate left the body via a puncture made in the left atrium.
Lungs were perfused for 2 minutes, excised and frozen at –80C to allow for later
analysis by confocal microscopy. To visualize, lungs were thawed in cold HBSS prior to
transfer to 0.1% paraphenylenediamine in HBSS for 10 minutes. Lungs were assessed
using a Zeiss LSM 410 confocal microscope, and Carl Zeiss LSM 3.99 software. The
presence of tumor cells was determined using green fluorescence and the focal plane
containing the largest volume of tumor cells was identified. At that same focal plane, the
lung then was scanned for red fluorescence to identify thrombi. The green and red
fluorescence were quantified in pixels by a blinded observer using ImageJ 29, and the ratio
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of thrombus to tumor cell area was determined. To ensure that visualized red
fluorescence was due to thrombus formation and not accumulation of fluorescent
fibrinogen that was not cleared, potentially due to vessel blockage by tumor cells, inert
plastic microspheres (20 m, Polysciences, Pennsylvania) were injected. Use of these
microspheres in platelet-restoration experiments allowed examination of lung tissue for
non-specific thrombus formation following platelet injection.

3.3.7 Histology
Spleens were collected and weighed; long bones were stripped of muscle tissue prior to
fixation of tissues in 10% buffered formalin. Bones were decalcified in Cal-Ex II
(Fischer Scientific, New Jersey) solution prior to H&E staining of 3 µm sections.
Megakaryocyte quantification was carried out by a trained observer under pathologist
guidance.

3.3.8 Statistical analysis
The Student's unpaired t test and one-way ANOVA with a Tukey‟s Multiple Comparison
post-test were used to compare between animal groups. The Pearson‟s rank correlation
was used to determine relationships between various variables. All statistics were
calculated using GraphPad Prism 4. A two-sided p < 0.05 was considered statistically
significant.

3.4 Results
3.4.1 Primary tumor presence decreases metastasis
To evaluate the effect of a primary tumor on early steps in the development of
metastases, we quantified metastases using a modified model of experimental metastasis.
Animals first received an intradermal (i.d.) injection of B16F10 cells (primary tumor
group) or cell vehicle (tumor-naïve group). After sixteen days, all animals received a
secondary injection of B16F10-LacZ cells via the lateral tail vein to target cells directly
to the lung. This experiment was repeated multiple times with similar results;
representative data is presented here. Primary tumors were 533.5  33.2 mm3 at the time
of secondary injection. We found that the presence of a primary tumor significantly
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inhibited experimental lung metastasis, as six days following secondary injection there
were fewer X-gal positive lung surface metastases in primary tumor-bearing mice as
compared to tumor-naïve animals (Figure 3.1 A). Very few lung metastases were not
positive for X-gal (3 metastases in all mice examined), and these tumors were
significantly larger than the other metastases visualized. It was assumed that these rare
metastases arose from seeding by the primary tumor and were not included in subsequent
quantification. X-gal positive metastases that did form in the primary tumor group were
significantly smaller than those in the tumor-naïve group (Figure 3.1 B), indicating that
the primary tumor is not only impeding survival of arrested cells, but also the growth of
cells that do persist.

3.4.2 Primary tumor decreases thrombus formation following
metastatic cell arrest
Previous work in our and other laboratories14, 17, 18 has shown that efficient metastasis of
B16F10 cells is dependent on thrombus formation at the cell surface following arrest in
the lung microvasculature. Therefore, we evaluated the ability of B16F10-LacZ cells to
stimulate thrombus formation following arrest in the lung of tumor-bearing and tumornaïve animals. Using a previously developed confocal microscopy technique14, we found
that the presence of a primary tumor significantly reduced the size of thrombi that formed
4-hours after secondary cell injection as compared to tumor-naïve animals (pictured in
Figure 3.2 A and B, quantified in Figure 3.2 C).

3.4.3 Primary tumor causes systemic changes including decreased
platelet number and splenomegaly
To determine the mechanism by which the presence of a primary tumor inhibited
thrombus formation around i.v. injected cells, the number of circulating platelets was
quantified in tumor-naïve and tumor-bearing animals. Sixteen days following primary
injection, blood was pulled via cardiac puncture for analysis. It was found that primary
tumor-bearing mice had significantly fewer circulating platelets than tumor-naïve animals
(Figure 3.3 A). Primary tumor-bearing mice were also found to have significantly
enlarged spleens upon sacrifice at day 16 (Figure 3.3 B), and spleen size significantly
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Figure 3.1 The presence of an intradermal B16F10 primary tumor significantly
reduced lung metastasis from a secondary i.v. injection of B16F10-LacZ cells.
(A) Animals that received an i.d. injection of B16F10 cells had fewer lung metastases
than animals that received a sham i.d. injection (n = 10-12/group; t-test p < 0.05). (B)
Lung metastases that developed in tumor-bearing mice were significantly smaller than
those in tumor-naïve animals (n = 4/group, randomly chosen from animals in (A); t-test p
<0.005). Columns, mean; bars, SE.
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Figure 3.2 The presence of an intradermal
B16F10 primary tumor reduced the association
between thrombi and B16F10-LacZ cells in
mouse lung microvasculature.
B16F10-LacZ tumor cells were labeled in vitro with
CMFDA to provide green fluorescence. Animals
received AlexaFluor647 conjugated fibrinogen prior to
injection of fluorescent B16F10-LacZ cells to allow
incorporation of fluorescent fibrin into thrombi.
Representative confocal images taken from (A) tumornaïve and (B) tumor-bearing animals. Scale 20 m.
(C) Quantification of confocal microscopy images
taken from tumor-naïve and tumor-bearing animals (n
= 4/group), (t-test, p< 0.05). Images are expressed as a
ratio of red:green, or amount of thrombus to amount of
tumor cell present. Columns, mean; bars, SE.
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correlated positively with primary tumor weight (Figure 3.3 C) and negatively with
platelet number (Figure 3.3 D). Tumor weight showed a trend towards a negative
correlation with the number of circulating platelets (Figure 3.3 E), but this did not reach
statistical significance. Histological analysis of spleens from tumor-bearing and tumornaïve animals was performed to further assess the interplay between the primary tumor
and the spleen. Normal spleen histology was observed in tumor-naïve animals (Figure
3.4 A and B), but it was found that the spleens isolated from tumor-bearing animals
showed extensive extramedullary hematopoiesis, with tri-lineage precursors throughout
the red pulp, distorting the splenic architecture and decreasing white pulp presence
(Figure 3.4 C & D). In particular, there was an abundance of megakaryocytes and their
precursors (Figure 3.4 D vs. 3.4 B). The observed splenomegaly (Figure 3.3 B) was thus
at least in part due to marked extramedullary hematopoiesis, and may have been
secondary to platelet consumption in tumor bearing animals.
To further investigate the effect of the primary tumor on platelet manufacture, long bones
of primary tumor-bearing and tumor-naïve animals were removed and the number of
megakaryocytes was quantified in histologic slides. Contrary to the spleen histology,
there was no effect of the primary tumor on the number of megakaryocytes in the long
bones (data not shown), indicating that the tumor-stimulated platelet manufacture is in
the spleen alone, as is common during murine stress27.

3.4.4 Re-establishment of platelet number in primary tumor-bearing
mice restores thrombus formation
To determine if reduction in platelet number was functionally responsible for the
decrease in lung metastasis, we strove to re-establish a normal platelet count in tumorbearing mice. To this end, we isolated platelets from donor mice and injected them into
tumor bearing animals sixteen days following primary tumor introduction. We
concentrated platelets from 3 mL or 6 mL of blood prior to injection and found that
platelets isolated from 6 mL of mouse blood was required to fully restore the number of
circulating platelets in tumor-bearing animals (Figure 3.5 A). We next wanted to
determine if this platelet injection allowed functional thrombus formation in response to
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Figure 3.3 Interaction between a B16F10 primary tumor and platelet turnover.
(A) Quantification of circulating platelets in tumor-naïve and tumor-bearing animals.
Animals with a B16F10 primary tumor had significantly fewer platelets sixteen days
following i.d. injection (n = 12/group, t-test p <0.05). (B) Tumor bearing mice were
found to have significantly enlarged spleens as compared to tumor naïve animals (n= 1756/group, t-test p < 0.005). Additionally, spleen weight correlated with both (C) tumor
size (n = 56, Pearson‟s p < 0.05, r = 0.31) and (D) platelet count (n = 12, Pearson‟s p <
0.05, r = -0.68). (E) Correlation between tumor size and platelet count did not reach
significance (n = 12, Pearson‟s p = 0.29, r = -0.33).
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Figure 3.4 Histological analysis of splenic tissue isolated from tumor-naïve (A, B)
and tumor-bearing (C, D) animals.
Normal splenic structure is seen in tumor-naïve animals, with distinct red (R) and white
pulp (W). Hypercellularity is seen in the red pulp of spleens isolated from tumor-bearing
animals, with reduction of white pulp. Higher power magnification shows normal red
pulp in tumor-naïve spleen (B), marked tri-lineage extramedullary hematopoeisis, with a
particular abundance of megakaryocytic precursors (arrows) in tumor-bearing animals
(D).
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secondary cell injection. Intravenous injection of AlexaFluor647-conjugated fibrinogen
prior to injection of unlabeled platelets or vehicle and CMFDA-labeled tumor cells
allowed visualization of all thrombi formed in response to B16F10-LacZ tumor cells.
Using confocal microscopy, we evaluated thrombus formation in tumor-naïve and tumorbearing mice following platelet vehicle injection, and tumor-bearing mice after platelet
injection. Injection of platelets isolated from 6 mL of blood was capable of restoring
thrombus formation in primary tumor-bearing mice to levels equivalent to tumor-naïve
animals (Figure 3.5 B-E). To confirm that visualized thrombi were specific to tumor cell
interaction and did not arise from injection of isolated platelets, a subset of tumor naïve
animals received i.v. injection of fluorescent fibrinogen prior to injection of isolated
platelets. These animals did not receive B16F10-LacZ cells; rather they received an i.v.
injection of 20 m inert fluorescent microspheres. Arrest of these spheres did not result
in thrombus formation or spontaneous fluorescent fibrinogen accumulation (Figure 3.5
F). This indicates that the thrombi observed following tumor cell injection are due to
interaction between B16F10-LacZ cells and circulating coagulation factors.

3.4.5 Normal platelet count required for B16F10 metastasis
Given that injection of platelets restored functional coagulation at the metastatic cell
surface, we quantified lung metastasis formation in mice following platelet injection.
Sixteen days after mice received a primary tumor or sham injection, animals received an
i.v. injection of platelets or vehicle five minutes prior to i.v. injection of B16F10-LacZ
cells. Six days following secondary cell injection, the number of lung surface metastases
was quantified.
Tumor-naïve mice that received the platelet vehicle were found to have fewer metastases
as compared to un-injected, tumor-naïve mice (Figure 3.6). This was not surprising given
the anti-coagulant component of the platelet vehicle (EDTA). Importantly, tumorbearing mice that received platelets showed more lung metastases than tumor-naïve
animals that received platelet vehicle, and showed equivalent metastasis to un-injected
tumor-naïve mice, indicating that the re-establishment of platelet number was capable of
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Figure.3.5 Injection of isolated murine platelets re-established circulating platelet
number and restores thrombotic tumor emboli.
(A) Platelets isolated from donor mice were injected into tumor-bearing mice and the
number of circulating platelets was determined. Injection of platelets concentrated from 6
mL of whole blood was required to acquire platelet numbers that were not significantly
different from tumor-naïve animals. Functional thrombus formation was determined
using confocal microscopy. B16F10-LacZ tumor cells were labeled in vitro with
CMFDA to provide green fluorescence. Animals received AlexaFluor647-conjugated
fibrinogen prior to injection of fluorescent B16F10-LacZ cells, to allow incorporation of
fluorescent fibrin into thrombi. (B) Quantification of confocal microscopy images taken
from tumor-naïve and tumor-bearing animals following platelet vehicle injection, and
tumor bearing animals following platelet injection (n = 4/group). Injection of platelets
concentrated from 6 mL of whole blood restored functional thrombus formation in
response to B16F10-LacZ cell injection (ANOVA, Tukey’s post test, n.s. from tumornaïve group, p < 0.05 from tumor vehicle group). Columns, mean; bars, SE.
Representative confocal images taken from (C) tumor-naïve, (D) tumor-bearing and (E)
tumor-bearing animals following platelet injection. (F) Control animals that received
platelets and fluorescent fibrinogen were given an injection of inert fluorescent
microspheres to test for non-specific thrombus formation. No accumulation of fibrinogen
was seen. Scale bar 20 m.

80

81

Figure 3.5 Reconstitution of platelet number in tumor-bearing animals reestablished lung metastasis formation.
Tumor-naïve animals received an i.v. injection of platelet vehicle and tumor-bearing
animals received an i.v. injection of platelet vehicle or isolated platelets prior to i.v.
B16F10-LacZ cell injection (n = 12/group). Platelet vehicle injection into tumor-naïve
animals reduced metastasis number as compared to control (un-injected naïve and
primary data are historical controls from Fig 1A) (ANOVA, Tukey‟s post test, p < 0.05).
Vehicle injection into tumor-bearing mice did not further reduce metastasis from that
seen previously in tumor-bearing animals (p > 0.05). Platelet injection into tumorbearing mice showed an increase in lung metastasis as compared to vehicle injected
tumor-bearing animals (p < 0.05) and restored lung metastasis number to that seen in
tumor-naïve animals (p > 0.05). Columns, mean; bars, SE.
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restoring lung metastasis of B16F10-LacZ cells and was able to counteract the effect of
the presence of a B16F10 primary tumor (Figure 3.6).

3.5 Discussion
In this study, we established that the presence of a B16F10 primary tumor was capable of
significantly inhibiting the number and size of lung metastases arising from secondarily
injected B16F10-LacZ cells. This inhibition of metastasis was found to be due to a
primary-tumor mediated reduction in circulating platelet number, resulting in insufficient
thrombus formation in the lung following metastatic cell injection. Restoration of
circulating platelet number, through injection of platelets isolated from donor mice, reestablished thrombus formation in primary tumor bearing mice and allowed equivalent
metastasis formation in both primary tumor-bearing and tumor-naïve animals.
The negative impact of a B16F10 primary tumor on secondary metastasis was somewhat
surprising given that the B16 cell line has been reported to stimulate pre-metastatic niche
formation in the lung, liver, testis, spleen and kidney30. Recruitment of BMDC to
facilitate formation of a pre-metastatic niche is thought to aid metastasis formation, as
VEGFR1+ cell present in the niche increase adhesion and arrest of metastatic tumor cells.
Additionally, in vitro analysis found that B16 cells were increasingly mobile in response
to VEGFR1+ cells30. It is possible that B16F10 cells do not stimulate formation of the
pre-metastatic niche as seen with the B16 cells used by Kaplan et al.30, or that the
reduction in platelet number in primary tumor-bearing animals is able to inhibit
metastasis formation in spite of pre-metastatic niche presence. Development of
concomitant tumor resistance has been found to occur via immunogenic (small tumors,
immunogenic types) and non-immunogenic mechanisms (large tumors, anti-angiogenic
or anti-mitotic mechanisms)10, 31, 32, but the potential for a primary tumor to both inhibit
and promote metastasis through concomitant tumor resistance and pre-metastatic niche
formation requires further investigation. Importantly, in this study animals received the
second injection of tumor cells when the primary tumor was relatively small (~530 mm3)
such that the previously identified anti-angiogenic and anti-mitotic mechanisms of
concomitant tumor resistance found to occur after primary tumors reached 2000 mm3 11
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should not yet be involved. Additionally, immunogenic control is not thought to be
responsible for the suppression of B16F10 metastases seen here, as B16 cells were
derived from a spontaneously formed tumor and are poorly immunogenic12. Direct
analysis of tumor immunity in a B16 model found that it was induction of CD4+ CD25+
regulatory T cells that was responsible for the lack of prevented the development of
concomitant tumor immunity in C57Bl/6 mice12.
It is well established that platelets play an integral role in metastatic establishment33-35.
Following arrest in the vasculature, tumor cells stimulate thrombus formation at their cell
surface14, 16, 18. The interaction between tumor cells and thrombi provides valuable
adhesion contacts36, growth and survival factors and protection from host immune
surveillance16, 34. In pre-clinical studies, treatment of animals with an anti-coagulant such
as heparin14, 37 or hiruden17 prior to metastatic cell injection results in significant
reduction in pulmonary metastasis38. Previous work in our laboratory also found that
inhibition of serine-protease activity in vivo stabilized tumor cell-associated thrombi and
increased B16F10 metastasis formation14. Activated platelets were found to increase
invasiveness of human ovarian cancer cells39 and tumor cells that are able to stimulate
clot formation are more likely to be retained in the pulmonary vasculature as they are
more likely to form stable adhesive contacts and spread along the inside of the pulmonary
vasculature15. Induction of thrombocytopenia through injection of bacterial
lipopolysaccharide or neuraminidase significantly decreases lung metastasis of both
strongly and weakly immunogenic tumor types40. Interestingly, injection of platelets into
thrombocytopenic animals prior to i.v cell injection did not restore metastasis number,
potentially due to insufficient platelet injection, as evidence for platelet number rescue
was not presented40. The direct role of platelets in establishment of metastases has been
investigated in B16 and fibrosarcoma models with conflicting results. The positive
correlation between platelet aggregation and metastatic ability found in the B16F10 cell
line did not hold when individual B16F10 clones were generated and tested.41 Similar
clonal investigation with the PAK 17 fibrosarcoma cell line showed that highly metastatic
clones require platelet interaction for successful metastasis. This disparity could be due
to differences in analysis of platelet aggregating ability42, but could indicate that the most
aggressive B16F10 clones are capable of metastasis regardless of platelet interaction, due
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to other malignant characteristics. For example, those clones that exhibit high metastatic
ability without extensive platelet aggregation activity may form more extensive tumor
cell-tumor cell associations allowing for similar protection from immune surveillance for
the central cells as is provided by thrombus formation21. Alternatively, these cells may
indirectly stimulate platelet aggregation in vivo, which would not be readily detectable in
vitro. In general these two studies identified that high platelet aggregating ability is not
sufficient for metastasis of non-metastatic cells41, and indicate that tumor cell-thrombus
association is an important determinant in metastatic potential42.
Interestingly, the splenomegaly identified in tumor-bearing animals was associated with
tri-lineage extramedullary hematopoiesis, with a preponderance of megakaryocytic
precursors. A similar increase in hematopoiesis was not found in the bone marrow of
tumor-bearing mice, which is in accordance with normal murine physiologic response.
During stress, the majority of (reactive) hematopoiesis is performed in the murine
spleen27. Despite the increase in platelet manufacture in the spleen, the number of
circulating platelets was significantly decreased in tumor-bearing mice, indicating that
the spleen was unable to replenish the platelets being lost.
Several possibilities exist for the cause of the platelet consumption and resulting
thrombocytopenia in this case. B16F10 murine melanoma cells express TF on their cell
surface23, 43, therefore the cells within the tumor may activate circulating platelets
resulting in thrombus formation at the primary tumor site. B16F10 primary tumors tend
be hemorrhagic with a necrotic core void of much secondary structure, and can lead to
extensive bleeding with even minor trauma (unpublished observation). In addition, and
perhaps most importantly, the presence of a B16F10 primary tumor may stimulate
disseminated intravascular coagulation. Disseminated intravascular coagulation in cancer
is characterized by activation of the coagulation cascade in the defective tumor
vasculature or by pro-coagulant activity on tumor cells, or their membrane components,
and is the most common cause of thrombocytopenia in cancer patients34, 44. Local
fibrinogen and platelet consumption then lead to systemic deficiencies and increased
clotting time. Although human patients may be somewhat less susceptible to tumorassociated thrombocytopenia (thrombocytosis is the most common blood abnormality in
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cancer patients34, 35), mice are known to compensate poorly for blood or platelet loss and
easily develop anemia or thrombocytopenia following a minor insult27. Interestingly,
B16F10 cells have been found to generate large numbers of microvesicles (MV) in vitro;
isolation and injection of these MV prior to i.v. injection of B16F10 cells has been linked
to increased metastasis45. Given the cell surface expression of TF on B16F10 cells,23 it
would be anticipated that these MV would also contain TF. Therefore, it is possible that
injection of MV two-hours prior to injection of B16F10 cells45 could result in an increase
in tumor-cell associated thrombus formation, leading to an increase in metastasis. In the
presence of an ongoing release of TF-containing MV from a B16F10 primary tumor, it
would be anticipated that rather than a pro-metastatic effect of the MV, there would be
sustained activation of the coagulation cascade leading to platelet exhaustion and/or
depletion, as was seen here. Therefore the release of MV from the B16F10 primary
tumor may be partially responsible for the significant reduction in platelet numbers.
The integral role of coagulation in metastasis formation is further indicated by the effect
of anti-coagulant therapy in cancer patients. Preliminary clinical trials have shown a
significant increase in overall survival of patients randomized to receive LMWH versus
placebo46. Interestingly, long-term exposure to LMWH in patients with cancer-related
thrombosis only increased survival of those patients who did not have metastatic disease
at the time of study enrollment46. Additionally, large cohort analysis of overall
probability of death in those patients diagnosed with cancer as compared to those
diagnosed with cancer and thromboembolism, found that approximately 20% of patients
with cancer alone and 90% of patients with a combined diagnosis succumbed to their
disease within 6 months. It has been indicated that these deaths could be attributed to
three possible scenarios: 1) fatal recurrent pulmonary thromboembolism; 2) identification
of a coagulation disorder may simply be a surrogate marker for more aggressive
malignancy; 3) systemic aberrations in the coagulation pathway may result in a more
permissive tumor cell-host interaction giving rise to extensive tumor growth resulting in
the early death of the patient46. Given these data, further analysis of modulation of the
systemic coagulation pathway in cancer patients as a means to prevent metastasis
establishment and premature death is warranted.
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The development of metastases occurs in the midst of a complex interaction between a
primary tumor and the host - the full extent of which remains unknown. There is the
potential for a primary tumor to both promote metastatic progression through stimulation
of pre-metastatic niche formation, as well as to restrict metastasis through concomitant
tumor resistance. In this study, we identified a form of concomitant tumor resistance
known as athrepsia, which was in this case due to primary tumor-induced
thrombocytopenia and the resulting reduction in tumor-thrombus formation, with
inhibition of metastasis. Full understanding of the interplay between a primary tumor,
the host and forming metastases will be essential to the development of strategies to
inhibit metastatic progression, either before or after the surgical resection of the primary
tumor.
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Chapter 4

4

Primary tumor presence restricts metastatic
establishment in a murine model of human breast
cancer

4.1 Synopsis
Breast cancer is the most common cancer and the second most common cause of cancerrelated mortality in Canadian women. These deaths are not due to the presence of a
primary tumor however, but are caused by the spread of cancer cells to sites throughout
the body. These cells give rise to metastases that are present at the time of diagnosis, or
lead to tumor recurrence and patient relapse. Analysis of breast cancer patient data
acquired prior to the routine use of adjuvant therapies identified a pattern of breast cancer
recurrence that was independent of disease stage at the time of surgery and appears
synchronized with the time of tumor resection. It appears that removal of the primary
tumor causes a simultaneous initiation of metastatic growth through the release of growth
factors during the wound healing process, or that the primary tumor was somehow
restricting the growth of metastases and upon tumor resection, metastatic growth is no
longer suppressed. Alternatively, formation of a pre-metastatic niche, a cluster of bone
marrow host cells that forms a supportive metastatic environment, is initiated by proteins
released from a primary tumor. The pre-metastatic niche forms prior to the arrival of
metastatic cells and leads to increased tumor cell adhesion and growth. The phenomena
of pre-metastatic niche formation and primary tumor suppression of metastasis are
contradictory and together they indicate that the interaction between a primary tumor,
host systems, and metastatic cells is complex, and remains poorly understood. Previous
work in our laboratory has shown that a murine melanoma primary tumor is able to
restrict the development of secondary metastasis through alterations in systemic
hemostatic factors (Chapter 3). Therefore, we sought to evaluate the effect of an
established breast primary tumor on the early development of lung metastases to
determine if the metastatic inhibition seen previously also exists in a model of human
breast cancer
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In this study, we investigated the effect of a breast primary tumor on the early
development of lung metastases and found that tumor bearing animals developed
significantly fewer lung metastases than tumor-naïve control animals. Tumor-bearing
animals showed an increased number of VEGFR1+ cells in the lung, potentially
indicating BMDC recruitment due to expression of OPN. Preliminary data to determine
the mechanism of primary tumor-mediated inhibition of metastasis indicates that
successful metastasis may depend on activation of the host hemostatic system which may
be impaired in the presence of a primary tumor.
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4.2 Introduction
Breast cancer is estimated to account for 5400 deaths in Canada in 20101. These deaths
are not due to the primary tumor, but rather because of the spread of tumor cells from the
primary tumor to distant sites2. Those tumors that have reached a relatively large size
and/or have metastasized to several lymph nodes at the time of diagnosis carry a
significantly higher risk of recurrence compared early-stage tumors3.
Interestingly, analysis of patient data accumulated prior to the routine use of adjuvant
chemotherapy, has identified a two-peak pattern for recurrence3, 4. When all patients are
considered, regardless of tumor stage at diagnosis, there is a sharp peak of recurrences at
18 months post-surgery and another broad peak at 60 months3. This recurrence pattern
was identified in over 12 clinical studies, with varying peak amplitudes, but with an
identical timeline5, 6. More recent clinical data shows that this first peak no longer exists
at 18 months, but rather, the addition of adjuvant chemo- and radiation therapy has
shifted the major peak of recurrence to approximately 4 years7. The similar patterns of
recurrence in all patient groups regardless of disease stage at the time of surgery may
indicate a synchronization of metastatic development upon removal of the primary
tumor5. This synchronization could be due to the release of growth factors during wound
healing or a sudden removal of growth suppressive factors, such as angiostatin, with
resection of the primary tumor3, 5.
Concomitant tumor resistance, the ability of a primary tumor to restrict the growth of
secondary metastases, has been identified in several pre-clinical models of metastasis and
is thought to occur through three potential mechanisms8. First, the primary tumor may
prime the immune system to assist clearance of metastatic cells. Second, the primary
tumor may restrict the growth of distant metastases through production of anti-angiogenic
molecules such as angiostatin or TSP9. Third the primary tumor may systemically
deplete essential host factors, thereby preventing the growth of any other tumors8. The
first hypothesis would not explain the clinical breast cancer data, as cells shed prior to
tumor resection are not cleared by the immune system if they are able to cause recurrence
at later time points. The second or third hypothesis could explain the clinical recurrence
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pattern however. Removal of the primary tumor would eliminate the growth-suppressive
molecule responsible for holding metastases in check3 or could free up host factors
essential for metastatic growth. In both scenarios, removal of the primary tumor would
lead to a simultaneous growth initiation of distant metastases due to sudden removal or
availability of the key factor(s).
Alternatively, intriguing work published by McAllister, et al.10 showed that a human
breast cancer xenograft did not restrict the growth of other tumors or metastases, but
rather was capable of stimulating the growth of an otherwise-indolent transformed
mammary epithelial cell line (HMLER-HR). This growth stimulation was due to the
activation and mobilization of BMDC by OPN secreted from the stimulating primary
tumor. The activated BMDC colonized both the stimulating and indolent tumor sites
which allowed for supportive tumor stroma development and increased tumor growth10.
As further indication that a primary tumor can have a systemic effect, BMDC stimulation
by the presence of a primary tumor has also been described during pre-metastatic niche
formation. In this case, BMDC mobilization and colonization of distant normal tissues
occurs prior to the arrival of metastatic cells, and these BMDC develop into a supportive
environment which aids the arrest and development of metastases11-14.
The pre-clinical identification of pre-metastatic niche formation conflicts with the
observation that a primary tumor may hold metastatic growth „in check‟6, 7. Together,
these phenomena indicate that there is a complex interaction between a primary tumor,
secondary metastases and the host environment which remains poorly understood.
Previous work in our laboratory has shown that a murine melanoma primary tumor is
able to restrict the development of secondary metastasis through alterations in systemic
hemostatic factors (Chapter 3). Therefore, we sought to evaluate the effect of an
established breast primary tumor on the early development of lung metastases to
determine if the metastatic inhibition seen previously also exists in a model of human
breast cancer.
Using a variant of the human breast carcinoma MDA-MB-231 cell line with increased
metastatic ability (231LN), we found that the presence of a mammary fat pad (mfp)
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tumor reduced the number of lung metastases arising from a second intravenous
injection. The size of lung metastases that did develop was not affected, indicating that
the primary tumor may be affecting initial cell arrest or survival in the lung.
Immunohistochemistry analysis of lung tissue found that tumor bearing animals showed
increased presence of VEGFR1+ cells, indicating that 231LN cells may be capable of
stimulating pre-metastatic niche formation. Despite the presence of the metastasissupporting VEGFR1+ cells, the number of lung metastases present in tumor-bearing
animals was suppressed, therefore the inhibition of metastasis by the primary tumor
overwhelms the supportive role of VEGFR1+ cells. Preliminary data to identify the
mechanism behind the inhibition of metastasis by a primary tumor indicates that in
accordance with previous work from our laboratory, successful metastasis may depend on
activation of the host hemostatic system which may be impaired in the presence of a
primary tumor.

4.3 Materials and Methods
4.3.1 Cell culture and transfections
MDA-MB-231-luc-D3H2LN (231LN) cells were purchased from Caliper Life Sciences
(Hopkinton, MA). They are a variant of the MDA-MB-231 cell line which contain a
luciferase-expressing gene and have a propensity to metastasize the lymph nodes, and
have a high endogenous OPN production. They were maintained in MEM (Gibco)
supplemented with 10% fetal bovine serum (FBS, Sigma, Mississauga, Canada), 1 mM
sodium pyruvate (Gibco) and 0.1 mM non-essential amino acids (Gibco) at 37C with
5% CO2. Two cell lines were generated from the 231LN cells, one carried no
fluorescence marker, the 231LN-scr cells and the other carried a stable red fluorescent
tdTomato marker. 231LN-tdTomato cells were generated by nucleofection of the MDAMB-231-luc-D3H2LN (231LN) with the tdTomato-containing pcDNA3.1 vector with a
hygromycin resistance gene, using Amaxa nucleofection technology (Amaxa, Koeln,
Germany) according to manufacturer‟s instructions. Briefly, 1 x 106 231LN cells were
resuspended in Cell Line Nucleofector Kit V (Amaxa), mixed with 2 μg cDNA and
pulsed with the program X-13, as suggested by the manufacturer. Immediately after
nucleofection, cells were transferred into wells containing pre-warmed (37C) culture
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medium (as above). Forty-eight hours post-nucleofection, cells were selected using 750
μg/ml hygromycin (Gibco), to create a stably tdTomato-transfected cell line. All cells
were routinely tested and confirmed to be free of mycoplasma contamination using the
Mycoplasma Plus PCR primer set (Stratagene, Cedar Creek, TX).

4.3.2 Primary tumor and metastasis assay
Each animal used in this assay received a mfp injection of either 231LN-scr cells or cell
vehicle, and all animals received an i.v. injection of 231LN-tdTomato to allow for
separation of metastases arising from the primary tumor or i.v. injection. 231LN-scr cells
were grown to 70-80% confluence, trypsinized and washed in cold Hanks Balanced Salt
Solution (HBSS, Invitrogen). For mfp injection, cells were resuspended in a 50%
Matrigel Matrix (BD Biosciences) solution with HBSS at a concentration of 4 x 107
cells/mL and 50 µL (2 x 106 cells) were injected. NIH III (nude-beige, Charles River,
Massachusetts) mice were lightly sedated with an intraperitoneal injection of
xylazine/ketamine (1.3 mg ketamine and .065 mg xylazine per 20 g body mass) and cells
were into the right thoracic mammary fat pad without an incision. As illustrated in
Figure 4.1, control animals received a mammary fat pad injection of 50% Matrigel matrix
(BD Biosciences) solution with HBSS following the same procedure. Primary tumors
were allowed to grow for 28 days, at which point all animals received a second cell
injection. Unanesthetized tumor-bearing and tumor-naïve mice received an intravenous
(i.v.) injection of 5 x 105 231LN-tdTomato cells in 100 l HBSS via the lateral tail vein.
Animals were sacrificed 6 days following i.v. injection and lung tissue was isolated and
snap-frozen to enable quantification of the number of lung surface metastases using
fluorescence.

4.3.3 Quantification of lung metastasis
The total number of red-fluorescent metastases was manually determined by a blinded
observer on intact lung lobes using an Olympus Inverted IX81 microscope. Area of
individual lung metastases was determined using the Olympus FluoView FV1000
coupled to the IX81 motorized inverted system microscope at the Victoria Research
Laboratory confocal microscope core facility. Images were acquired with maintained
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imaging parameters by a blinded observer and area of each metastasis was determined on
fluorescent images using ImageJ15.

4.3.4 Histology and Immunohistochemistry
Lung tissues were fixed in 10 % neutral buffered formalin and embedded in paraffin.
Sections were cut to 4 µm thickness and stained with H&E or with monoclonal rat antimouse VEGFR1 (R&D Systems, Minneapolis Mn; #MAB471,) diluted to 10 µg/mL for
one hour at room temperature, after heat-induced epitope retrieval. Secondary detection
was achieved by linking to biotinylated polyclonal rabbit anti-rat antibody (Dako,
Burlington Ontario; #E0468) diluted to 1:500 for thirty five minutes, followed by
labeling with StreptABComplex/HRP (Dako, Burlington Ontario; #K0377) and
diaminobenzidine (DAB). Positively-stained cells were counted by a blinded, trained
observer on an upright microscope on a 40x objective (Olympus BX45).

4.3.5 Western blot analysis of conditioned media
To confirm that OPN secretion from 231LN-scr cells did not differ from the parental
231LN cells, conditioned media was collected, concentrated and used in Western blots as
previously described16. Briefly, 231LN and 23LN-scr cells were grown to 70-80%
confluency, trypsinized and 5 x 105 cells were plated on 100 mm dishes. Plates were
incubated at 37C with 5% CO2 for 24 hours, then media was removed and plates washed
twice with PBS. Five millilitres of OPTIMEM was added to each and plates were
returned to incubator for a further 24 hours. OPTIMEM was drawn off and concentrated
using Amicon Ultra centrifugal filters with a 30 000 dalton molecular weight cut off
(Millipore; Billerica, MA). Cells were harvested from plates and counted using a
hemocytometer. Using the number of cells, volumes of conditioned media were
calculated to represent a specified number of cells (1 x 105), allowing conditioned
medium from equal numbers of cells to be loaded for Western blotting.
Western blots were carried out using the BioRad Mini Protean II Cell system.
Polyacrylamide gels (8%) were loaded with concentrated conditioned media with 5X
reducing loading buffer. After electrophoresis, separated proteins were transferred to
polyvinylidene fluoride (PVDF) membranes (Amersham, GE Healthcare; Baie d‟Urfe,
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QC). Membranes were blocked with 5% milk in TBS-T (tris-buffered saline with 0.1%
Tween) for one hour and after rinsing with TBS-T, were incubated with anti-OPN mAb
53 mouse monoclonal antibody (Assay Designs, Enzo Life Sciences; Plymouth, PA) at
1:1000 in TBS-T at 4C overnight. After rinsing three times with TBS-T, anti-mouse
(Amersham) secondary antibody was incubated at room temperature for one hour. After
rinsing three times with TBS-T, membranes were incubated with ECL Plus Western
Blotting Detection System (Amersham) and exposed to film in a dark room.

4.3.6 Flow cytometry
To compare TF expression between the parental MDA-MB-231 (ATCC), and 231LN-scr
and 231LN-tdTomato cell lines, all cells were grown to 70-80% confluency, trypsinized
and washed twice with cold flow buffer (PBS + 2% FBS). Cells were resuspended in
cold flow buffer (1 x 106 cells/mL) and separated into 100 µl aliquots. Cells were
incubated with 3 µl anti-tissue factor antibody (FITC-conjugated anti-human tissue
factor, 4508CJ American Diagnostica, Stamford, CT) or 4 µl control antibody to account
for non-specific binding (FITC-conjugated Mouse IgG1, 349041 BD Biosciences, San
Jose, CA) for 30 minutes with occasional vortexing. Cells were then washed twice with
excess volume PBS, resuspended in cold flow buffer prior to analysis on an EPICS XLMCL flow cytometer (Beckman Coulter, Mississauga, ON). A minimum of 1 x 105
FITC+ events were counted per sample.

4.4 Results
4.4.1 Primary tumor presence decreases lung metastasis
To evaluate the effect of a human breast adenocarcinoma primary tumor on the early
development of metastases, we utilized a modified model of experimental metastasis
where animals received both a primary and secondary tumor cell injection (Figure 4.1 a).
Animals first received a mammary fat pad injection of 231LN-scr cells (primary tumor
group) or cell vehicle (tumor-naïve group). After twenty-eight days, when primary
tumors had reached ~750 mm3 (Figure 4.1 b), all animals received a secondary injection
of 231LN-tdTomato cells via the lateral tail vein to target cells directly to the lung. The
fluorescent label in 231LN-tdTomato cells enabled delineation of metastases arising from

99

a

b

Figure 4.1 Timeline of primary tumor and metastasis injection model.
(a) Experimental model used to analyze the effect of a primary tumor on the early
development of metastases. Animals first received a mammary fat pad injection of
Matrigel (cell vehicle) or 231LN-scr cells suspended in Matrigel. Following primary
tumor establishment all animals received an i.v. injection of 231LN-tdTomato cells. Sixdays following i.v. injections all animals were sacrificed and lung and primary tumor
tissues were collected. (b) Primary tumor growth of 231LN-scr cells. Animals received
an i.v. injection of 231LN-tdTomato cells on day 28 of tumor growth when primary
tumors were approximately 750 mm3.
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the i.v. injection. We found that the presence of a primary tumor significantly inhibited
experimental lung metastasis, as six days following secondary injection there were fewer
red-fluorescent lung surface metastases in primary tumor-bearing mice as compared to
tumor-naïve animals (Figure 4.2 a). There was no difference in the size of those lung
metastases that did form in the primary tumor-bearing and tumor-naïve group (Figure 4.2
b). Histological analysis of lung tissue identified single tumor cells and small clusters of
tumor cells in both tumor-naïve and tumor-bearing animals (Figure 4.2 c and d), in
agreement with the small size of metastases determined using fluorescence microscopy.

4.4.2 BMDC recruitment to the lung
Previous reports have shown that expression of OPN from a primary tumor can stimulate
mobilization of BMDC to colonize primary tumor stroma10. It has also been shown that
proteins secreted from a primary tumor can stimulate VEGFR1+ BMDC recruitment to
form the pre-metastatic niche, which may lead to increased metastatic cell arrest and
growth12, 17. Therefore, we performed immunohistochemistry to determine if VEGFR1+
cells were present in the lung of primary tumor-bearing or tumor-naïve animals and if
these cells were found in association with 231LN-tdTomato cells. Quantification of
immunohistochemistry slides found significantly more VEGFR1+ cells in lung tissue of
primary tumor-bearing animals as compared to tumor-naïve controls (Figure 4.3 a).
Additionally, large clusters of more than fifteen VEGFR1+ cells were found in primary
tumor-bearing animals, potentially indicating the presence of a pre-metastatic niche
(Figure 4.3 b). These large clusters were not visualized in control lung tissue. Tumor
cells were found associated within the clusters of VEGFR1+ cells, either in small groups
of breast cancer cells or as single tumor cells in both primary tumor-bearing (Figure 4.3
c) and tumor-naïve animals (Figure 4.3 d).

4.4.3 OPN expression by 231LNscr cells
To determine if the increased presence of VEFGR1+ cells in the lung was due to secretion
of the BMDC-stimulating protein, OPN, Western blot analysis of conditioned media
samples was performed. It was found that 231LN-scr cells maintained a similarly-high
level of OPN secretion as the 231LN cells after extended in vitro culture (Figure 4.4),

101

a

c

b

d

Figure 4.2 Primary tumor presence significantly reduced pulmonary metastasis
(a) The presence of a 231LN-scr primary tumor significantly reduced the number of
231LN-tdTomato lung metastases as compared to tumor-naïve controls (n = 13-15/group;
t-test, p < 0.05). (b) Lung metastases in primary tumor-bearing animals were equivalent
in size to their tumor-naïve controls (n = 13-15/group; t-test, p > 0.05). (c) Histological
analysis showed isolated tumor cells (arrowhead) or (d) small clusters of tumor cells
(outline) in both primary tumor-bearing and tumor-naïve animals. Scale 50 µm.

102

a

c

b

d

Figure 4.3 Primary tumor presence increases the number of VEGFR1+ cells in the
lung.
(a) Quantification of immunohistochemistry staining for VEGFR1 identified a
significant increase in the number of VEGFR1+ cells in the lung of primary tumorbearing animals (n = 8/group, t-test p < 0.005). Large clusters of more than 15 VEGFR1+
cells were only visualized in primary tumor-bearing mice (b) and tumor cells (arrow
heads) were found associated within the clusters of VEGFR1+ cells in both primary
tumor-bearing (c) and tumor-naïve animals (d).
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therefore the increased presence of VEGFR1+ cells may be due to BMDC recruitment
stimulated by OPN secretion. Interestingly, despite the increased presence of potentially
metastasis-promoting VEGFR1+ cells17, primary tumor-bearing animals showed reduced
metastasis (Figure 4.1 a).

4.4.4 Tissue Factor expression
Previous work in our laboratory has shown that a B16F10 murine melanoma primary
tumor inhibits metastatic establishment through depletion of circulating platelet numbers
(Chapter 3). High levels of TF on the surface of B16F10 cells18 results in thrombus
formation following arrest of these cells in the lung, which is essential for metastatic
spread (Chapter 3). Therefore, expression of TF on 231LN-scr and 231LNtdTomato cells was evaluated by flow cytometry. It was found that in accordance with
previously published MDA-MB-231 parental cell data19, MDA-MB-231 cells (Figure 4.5
a) as well as both the 231LN-scr (Figure 4.5 b) and 231LN-tdTomato (Figure 4.5 c) cell
lines indeed express TF, indicating that these cells should be capable of stimulating
thrombus formation, and successful thrombus formation may play a key role in the
establishment of lung metastases, as has been found previously for MDA-MB-23119.

4.5 Discussion
The ability of a primary tumor to impact the development of metastases can take two
forms. Through stimulation of a pre-metastatic niche a tumor can increase metastatic
establishment, or through concomitant tumor resistance a tumor can prevent successful
metastasis. In this study, we determined that the presence of a 231LN-scr mammary fat
pad primary tumor significantly inhibited the early establishment of 231LN-tdTomato
lung metastases. This inhibition is likely due to a decrease in sustained cell arrest or
survival in the lung vasculature rather than an inhibition of growth, as the size of those
metastases that did develop was unaltered by the presence of a primary tumor. As has
been demonstrated with B16 cells17, the 231LN-scr primary tumor led to a significant
increase in the number of VEGFR1+ cells in the lung, potentially due to OPN secretion
and stimulation of BMDC recruitment. The presence of VEGFR1+ cells has previously
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been reported to increase lung metastasis through initiation of pre-metastatic niche
formation, yet in this study, the presence of a primary tumor inhibited metastasis. The
mechanism behind the significant decrease in metastasis remains unclear, but appears to
override the metastasis-stimulating effect of VEGFR1+ cells.
As outlined in Chapter 3, the presence of a B16F10 melanoma primary tumor was found
to inhibit lung metastasis formation due to a significant reduction in the circulating
platelet numbers in tumor-bearing animals. This led to an impairment of tumor cell
surface-thrombus formation following i.v. injection of B16F10-LacZ cells. Restoration
of the platelet number re-established thrombus formation as well as lung metastasis.
Given that the B16F1018, 231LN-scr, and 231LN-tdTomato cells all express TF on the
cell surface and the importance of thrombus formation in successful B16F10 metastasis,
it is possible that thrombus formation may play a key role in metastasis of 231LN cells.
The presence of a 231LN-scr primary tumor may result in a similar depletion of
circulating platelets as seen in the B16F10 model. Analysis of circulating platelet
numbers in 231LN-scr tumor bearing animals is ongoing in our laboratory.
The inability to form a thrombus during metastasis in the B16F10 model system may lead
to an increase in NK-mediated cell killing20 as C57Bl/6 mice are fully immunocompetent.
In the 231LN model however, the NIH III animals do not have functional T-cells, B-cells
or NK cells21, making it improbable that increased immune surveillance in the absence of
thrombus formation leads to the reduction in metastasis seen here. Thrombus formation
is also known to result in increased stable cell adhesion in the lung22, 23, therefore the lack
of thrombus formation may result in an increased number of cells passing through the
lung capillary bed or increased cell death due to anoikis from lack of stable adhesion24.
Unlike other examples of concomitant tumor resistance where the release of antiangiogenic molecules restricts metastatic growth9, it is not anticipated that inhibition of
angiogenesis is responsible for the decrease in metastasis seen here. First, there was no
size difference between metastases quantified in the tumor-bearing and tumor-naïve
animals. Second, metastases found in both primary tumor-bearing and tumor-naïve
animals were very early in development and were less than 1 mm in diameter and
therefore have not reached a size where they need to recruit their own blood supply25, 26.

105

Additionally, previous work in a fibroscarcoma model has found a biphasic pattern of
concomitant tumor resistance27. It was found that an immunogenic tumor (MC-C
fibrosarcoma) is capable of stimulating increased immune surveillance of metastatic cells
when the primary tumor is less than 500 mm3 and is capable of restricting metastatic
growth through inhibition of angiogenesis when the same tumor was greater than 2000
mm3 27. Primary tumors between 500 and 1500 mm3 had no effect on metastatic
progression27. In the 231LN model used here, primary tumors were approximately 750
mm3 at the time of the second injection and therefore were within the range when no
significant effect on metastasis was identified previously. It is unknown if the MC-C
fibrosarcoma cell line expresses TF or if it is highly thrombogenic, though a difference in
TF expression may account for the differential pattern of inhibition seen between the
MC-C and the B16F10 (Chapter 3) and the 231LN-scr cell lines.
The MDA-MB-231 cell line has previously been shown to stimulate BMDC migration to
tumor sites10, and to the pre-metastatic niche12. Expression of OPN from the MDA-MB231 cell line was found to mobilize BMDCs and stimulated their colonization of primary
tumor sites, which led to growth instigation in an otherwise-indolent cell line10.
Additionally, expression of lysyl oxidase by a MDA-MB-231 primary tumor led to
increased collagen IV crosslinking and increased CD11b+ myeloid cell recruitment to the
lung12. These essential components of the pre-metastatic niche increased metastatic cell
recruitment and tumor cell invasion12. Here, we found a significant increase in
VEGFR1+ cells in the lung of primary tumor-bearing animals, but this increase was
unable to promote metastasis, or was unable to overcome the inhibitory influence of the
primary tumor.
Histological analysis identified the presence of VEGFR1+ cells in both tumor-naïve and
primary tumor-bearing animals, and association of these cells with tumor cells in both
animal groups. Larger numbers of VEGFR1+ cells and the presence of clusters of more
than fifteen VEGFR1+ cells were only identified in primary tumor-bearing animals,
potentially indicating the presence of a pre-metastatic niche. This niche formation could
be due to expression of OPN from the 231LN-scr primary tumor. Further analysis of
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Figure 4.4 Western blot analysis of conditioned media from 231LN and 231LN-scr
cells.
23lLN and 231LN-scr cells were cultured in vitro for 4-weeks prior to isolation of
conditioned media to determine secreted OPN levels. Control transfection with a
scrambled shRNA sequence does not appear to have affected OPN expression, as similar
levels of OPN secretion were found in the 231LN and 231-scr cell conditioned media.
Multiple bands of OPN protein are present between 70 and 95 kDa.
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TF - FITC Log fluorescence
Figure 4.5 Flow cytometry analysis of TF expression.
Analysis of cell surface expression of TF by flow cytometry showed that all MDA-MB231 (a), 231LN-scr (b) and 231LN-tdTomato (c) cells express high levels of TF. Grey
curves represent control IgG1 antibody; black curves represent TF-specific antibody.
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lung tissue is required to determine if other hallmarks of the pre-metastatic niche are
present, such as increased FN deposition from fibroblasts, presence of VEGFR2+ or the
presence of CD11b+ myeloid cells. Additionally, we are analyzing the 231LN-scr cell
line to determine the expression level of several molecules thought to be important in
stimulating pre-metastatic niche formation. Along with OPN, TNF, TGFβ, VEGF and
PlGF have all been implicated in BMDC activation and mobilization resulting in premetastatic niche establishment14.
Along with the metastasis-promoting protein, OPN, 231LN cells were shown to express
TF on their cell surface, indicating that they may depend on thrombus formation for
successful metastasis. Establishing if the presence of a 231LN-scr primary tumor reduces
circulating platelet numbers, as seen in the B16F10 model (Chapter 3), will be essential
to determine if a common mechanism of metastatic inhibition exists in those tumor types
that express high levels of TF. If so, this would indicate that initiation of anti-coagulant
therapy may prevent metastatic establishment prior to primary tumor resection, and
extended treatment with low dose anti-coagulant therapies may provide long-term clinical
benefit.
The mechanism behind the decrease in metastasis identified here remains unclear and is
being investigated in ongoing work in our laboratory. Other ongoing work to elucidate
the mechanism behind metastatic inhibition includes time course analysis following
metastatic cell injection to determine if the presence of a primary tumor inhibits initial
cell arrest, sustained cell arrest, or tumor cell survival in the lung. Extra-pulmonary
organs will also be evaluated to determine if iv-injected 231LN-tdTomato cells do indeed
pass right through the lung capillary bed and reach distant viscera more frequently in
primary tumor-bearing animals. Previous work with anticoagulants has shown that
inhibition of coagulation can lead to impaired cell arrest and reduced pulmonary
metastasis28.
Understanding the mechanism behind primary tumor inhibition of metastasis will prove
invaluable in elucidating the interactions between primary tumor, the host, and
metastases. Significant breakthroughs in treatment options could result, as it may be
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possible to restrict metastatic growth by providing or removing the essential factor(s)
following primary tumor resection, leading to continued metastatic inhibition.

110

4.6 References
1. Marrett L, Dryer D, Logan H, Mery L, Morison H, Schacter B, Villeneuve G,
Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer
Statistics, 2007.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of
cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
3. Retsky M, Demicheli R, Hrushesky WJ. Does surgery induce angiogenesis in
breast cancer? Indirect evidence from relapse pattern and mammography paradox. Int J
Surg 2005;3:179-87.
4. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast
cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
5. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and
surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin
Pract Oncol 2007;4:699-710.
6. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of
surgery on tumor growth: a century of investigations. Ann Oncol 2008;19:1821-8.
7. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer:
an update. Breast Cancer Res 2007;9:208.
8. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor
challenge. Advances in cancer research 1983;39:71-120.
9. Folkman J. Angiogenesis inhibitors generated by tumors. Molecular medicine
(Cambridge, Mass 1995;1:120-2.
10. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA,
Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA. Systemic endocrine
instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005.
11. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche.
Cancer Res 2006;66:11089-93.
12. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia
AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment
to form the premetastatic niche. Cancer Cell 2009;15:35-44.
13. Psaila B, Kaplan RN, Port ER, Lyden D. Priming the 'soil' for breast cancer
metastasis: the pre-metastatic niche. Breast Dis 2006;26:65-74.
14. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for premetastatic niche formation: old sayings and new thoughts. Semin Cancer Biol;21:139-46.

111

15. Rasband WS. ImageJ Bethesda, Maryland, USA: National Institutes of
Health, 1997-2006:http://rsb.info.nih.gov/ij/.
16. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB,
Chambers AF, Allan AL. The thrombin inhibitor Argatroban reduces breast cancer
malignancy and metastasis via osteopontin-dependent and osteopontin-independent
mechanisms. Breast Cancer Res Treat 2008;112:243-54.
17. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C,
MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, et al. VEGFR1-positive
haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature
2005;438:820-7.
18. Kirszberg C, Lima LG, Da Silva de Oliveira A, Pickering W, Gray E,
Barrowcliffe TW, Rumjanek VM, Monteiro RQ. Simultaneous tissue factor expression
and phosphatidylserine exposure account for the highly procoagulant pattern of
melanoma cell lines. Melanoma research 2009;19:301-8.
19. Berny-Lang MA, Aslan JE, Tormoen GW, Patel IA, Bock PE, Gruber A,
McCarty OJ. Promotion of experimental thrombus formation by the procoagulant activity
of breast cancer cells. Phys Biol;8:015014.
20. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ,
Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and
circulating hemostatic factors cooperate to increase metastatic potential through natural
killer cell-dependent and-independent mechanisms. Blood 2007;110:133-41.
21. Oncology Animal Models. In: Laboratories CR, ed., vol. 2011 Wilmington,
Massachusetts, 2011.
22. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, Muschel RJ.
Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early
metastatic colony formation. Cancer Res 2004;64:8613-9.
23. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL,
Bugge TH. Fibrinogen is an important determinant of the metastatic potential of
circulating tumor cells. Blood 2000;96:3302-9.
24. Reijerkerk A, Voest EE, Gebbink MF. No grip, no growth: the conceptual
basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 2000;36:1695-705.
25. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases:
balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat
Med 1995;1:149-53.
26. Folkman J. Incipient angiogenesis. Journal of the National Cancer Institute
2000;92:94-5.

112

27. Franco M, Bustuoabad OD, di Gianni PD, Goldman A, Pasqualini CD,
Ruggiero RA. A serum-mediated mechanism for concomitant resistance shared by
immunogenic and non-immunogenic murine tumours. British journal of cancer
1996;74:178-86.
28. Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental
metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer
Res 1991;51:4549-56.

113

Chapter 5

5

General Discussion

5.1 Thesis summary
The interaction between tumor cells and the host is essential at all stages of cancer
progression, but is exceptionally important during metastasis. As cells move into the host
vasculature and are carried to distant organs, they encounter all new environments. To
withstand the challenges that these environments present, tumor cells must possess a
means of exploiting or avoiding the host response. This body of work demonstrates that
metastatic progression depends not only on the innate characteristics of the tumor cells,
but also on their ability to manipulate host systems. Intriguingly, the relationship
between host and tumor is not a simple tumor (promotion) versus host (inhibition), as this
work also demonstrates that in some cases it is the host which can promote metastasis,
while the primary tumor may inhibit metastatic progression. A major component of the
tumor-host interaction is the host hemostatic system, which plays a key role in metastatic
progression.
It has been well established that many cell lines (LLC and B16 in particular) depend on
thrombus formation for successful metastasis1-5. Direct activation of circulating
hemostatic factors through expression of TF by tumor cells is a key determinant of
metastatic potential by inhibiting NK cell-mediated clearance of micrometastases4, 5.
Indeed, inhibition of thrombus formation through treatment with anti-coagulants can lead
to a significant inhibition of pulmonary metastasis6, 7. In accordance with the important
role of hemostatic factors on metastasis, in Chapter 2 we demonstrated that treatment
with the anti-fibrionolytic agents aprotinin and EACA stabilized the interaction between
thrombi and tumor cells in the lung vasculature and increased pulmonary metastasis of
TF-expressing B16F10 cells. Importantly, previous pre-clinical analysis of aprotinin has
shown varying impacts on metastasis, depending on the model and cell line used, without
giving insight into its mechanism of action8-12. Several studies found that aprotinin could
decrease metastasis potentially through inhibition of tumor cell extravasation8, 12 but the
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work presented in Chapter 2 definitively shows that the survival benefit afforded by
increased interaction with thrombi while in the host vasculature outweighs any antimetastatic effects.
Chapter 2 also describes the development of a novel and highly-useful fluorescence
imaging technique where the interaction between tumor cells and thrombi are visualized
in the intact mouse lung. Through maintenance of experimental and imaging parameters,
the confocal images acquired can be used for quantification of this interaction. This
straightforward imaging protocol was also utilized in Chapter 3 to investigate the impact
of a primary tumor on the association between thrombi and metastatic cells and is easily
modified to apply to other model systems.
The data presented in Chapter 2 firmly establishes the importance of hemostasis in tumor
cell-host interactions during metastasis. In the clinical setting however, the interaction
between host and tumor cells may also be modulated by the presence of a primary tumor.
Pre-clinical investigation into the effect of a primary tumor on metastasis has shown that
the fate of metastatic cells can be largely dependent on the presence of a primary tumor13,
14

. Through stimulation of BMDC to form a pre-metastatic niche a primary tumor may

promote metastasis15, or it can cause a significant reduction in metastatic progression
through a phenomenon known as concomitant tumor resistance13. Differential expression
of metastasis-promoting (OPN16, lysyl oxidase17) or -inhibiting factors (angiostatin,
TSP18) from the primary tumor have been suggested to be responsible for these disparate
effects. In Chapter 3, we present a previously under-studied mechanism behind
concomitant tumor resistance, athrepsia – where the primary tumor usurps an essential
host resource thereby preventing metastatic growth19. In this study, we found a B16F10
primary tumor-induced thrombocytopenia in the host, which led to insufficient metastatic
tumor cell-thrombus association. Given the substantial benefit of this interaction to
metastasis, as identified in Chapter 2, it was not surprising that inhibition of this
thrombus association with metastatic cells by the primary tumor resulted in a reduction of
lung metastasis. Importantly, re-establishment of a normal circulating platelet number
was able to restore lung metastasis levels to that seen in tumor-naïve animals.
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Given that athrepsia has not been well established as a mechanism for concomitant tumor
resistance, there was concern that the phenomenon observed in Chapter 3 was specific to
the B16F10 cell line. Therefore, in Chapter 4 we sought to determine if a similar
phenomenon existed in a murine model of human breast cancer.
Utilizing a variant of the MDA-MB-231 human breast cancer cell line (231LN) we
evaluated the effect of a primary tumor on the development of metastases. Intriguingly,
the same pattern of metastatic inhibition by a primary tumor was identified in the 231LN
model. Additionally, the 231LN cells were found to express high levels of TF, indicating
that thrombus association may play a key role in their ability to form successful
metastases. An important difference between the B16F10 and 231LN models is the
immunocompetency of the host. B16F10 cells are syngeneic to and grow well in the
fully immunocompetent C57Bl/6 mouse strain. The 231LN cells, however are grown in
the NIH III strain, which have impaired T-, B- and NK cell function20. Although the
essential role for tumor cell-associated thrombi in metastasis in the B16F10 (syngeneic)
model may be related to increased NK cell surveillance of those cells not protected by
thrombi5, in the 231LN (NIH III) model this same tumor cell surveillance would not be
expected, given the lack of NK cell function. It is possible that in the 231LN model, a
decrease in thrombus formation leads to a reduction in metastatic cell retention in the
pulmonary vasculature7; ongoing investigation of early time points following i.v. tumor
cell injection will evaluate this possibility.
Interestingly, the presence of either a B16F10 or 231LN primary tumor led to the
development of fewer lung metastases, yet only in the B16F10 model were those lung
metastases of a smaller size. In both models, animals were sacrificed six days following
i.v. injection, yet the mean B16F10-LacZ metastasis size was approximately 18000 µm3,
whereas the 231LN-tdTomato metastases were only 300 µm3. The B16F10 cell line is
exceptionally aggressive, and most metastases had begun to form small colonies at the
time of sacrifice. The 231LN-tdTomato cells however, existed mainly as groups of 3-4
cells without showing signs of colony formation or extensive growth. Therefore, it is
possible that the 231LN primary tumor would also inhibit the growth of lung metastases,
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but this effect was not yet visualized because of the delayed growth initiation as
compared to the B16F10 cells.
Identification of concomitant tumor resistance in the both the B16F10 and 231LN models
was somewhat surprising, given the work showing that primary tumors arising from both
the B1615 and MDA-MB-23116, 17 cell lines are capable of stimulating metastasis through
BMDC mobilization. Intriguingly, we identified an increase in VEGFR1+ cells in the
lung of 231LN primary tumor bearing animals. It is not immediately clear why in our
study a 231LN primary tumor leads to an inhibition of metastasis, given the similar effect
on VEGFR1+ cells as in the work of Kaplan et al.15 and Erler et al. 17, but it may be due to
differences that arose following the in vivo passage and transfection of the 231LN cells
or due to inherent differences between mouse strains used. Our work was carried out in
NIH III animals with impaired T-, B- and NK-cell function20 whereas work published by
Erler, JT et al.17, 21 was carried out in nude (nu/nu) animals lacking T-cells20.
Importantly, it has been shown that the MDA-MB-231 cells22, 231LN and 231LN-scr
cells all express OPN, a key secreted protein required for BMDC mobilization and
colonization of distant tissues. It is possible that the pre-metastatic niche formed in
response to 231LN-scr cells does not contain other essential components such as FN or
CD11b+ myeloid cells15, 17, therefore as part of ongoing work within our laboratory we
are analyzing the lung tissues of primary tumor-bearing and tumor-naïve animals to
potentially identify other facets of the pre-metastatic niche.
The work presented in this thesis illustrates the importance of tumor cell-host interactions
in the establishment of metastases. The roles of each player are not clearly defined as
tumor versus host with the tumor stimulating metastatic progression and the host striving
to inhibit it – as shown in Chapters 3 and 4, the primary tumor may actually inhibit
metastasis formation through alterations in host hemostasis. Metastatic progression
appears to exist in a delicate balance between promotion and inhibition of metastasis by
the primary tumor through interaction with host systems. Further understanding of this
ability of a primary tumor to manipulate hemostasis will be invaluable in gaining insight
into tumor progression and the global nature of metastasis.
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5.2 Experimental Implications
5.2.1 Hemostasis in cancer progression
Most cancer patients with metastatic disease also show some degree of coagulopathy23, 24.
Perturbations in hemostatsis may occur as a result of surgery, reduced patient mobility,
chemotherapeutics or anti-angiogenic drugs, or because of blood flow disruptions
through the tumor(s) due to aberrant vascular structures25. Additionally, as tumors
become increasingly aggressive, there can be a pro-coagulant conversion of cancer cells
characterized by increased expression of TF or CP. Several oncogenes are responsible
for driving transcription of TF, and for increasing microvesicle release, which can also
drive systemic coagulopathy (reviewed in 25). Investigation of the role of TF in cancer
progression has shown that TF expression can be a marker of tumor stage and severity, as
high TF expression correlates with poor patient outcome in colorectal and prostate
cancer. Additionally, it can be used as a predictor of pro-thrombotic risk26. Pre-clinical
investigation has shown that TF expression is not a key determinant of primary tumorforming ability, but can be essential for pulmonary metastasis4, 25. In Chapter 3 we
identify an additional effect of TF-expressing cancer cells – that pro-coagulant activity of
a primary tumor can perturb host hemostasis leading to thrombocytopenia, prior to the
involvement of metastatic cells. Given the striking effect of thrombocytopenia on the
association between tumor cells and thrombi, and the subsequent inhibition of metastasis
seen in Chapter 3, clinical treatment to mimic this effect with anti-coagulants or through
platelet depletion could lead to a similar inhibition of metastasis. Identification of those
patients with high TF expression in primary tumor tissue or on circulating microvesicles
might identify those patients who would benefit from anti-coagulant therapy, even in the
absence of symptoms of altered hemostasis. Early treatment of with anti-coagulants
might prevent metastasis from a primary tumor that has acquired a pro-thrombotic
phenotype but has not yet metastasized. It may also prevent the formation of VTE deep
vein thromboses by identifying patients who would be prone to thrombotic events prior to
symptom presentation.
Additionally, knowledge of TF expression prior to tumor resection may allow the
physicians to make an informed decision regarding the inclusion of anti-fibrinolytic
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agents at the time of surgery. If a patient is identified as having a pro-thrombotic
expression pattern, it is more likely that those cells shed from that primary tumor will
exploit host hemostatic systems to successfully metastasize. By the same reasoning, it
may be also be advisable to avoid treatment with agents that would stabilize the
interaction between metastatic cells and thrombi, as shown in Chapter 2, as stabilization
of this interaction may lead to a significant increase in metastasis.

5.2.2 Concomitant tumor resistance and murine models of metastasis
Investigation of metastasis is generally performed using two types of experimental
models, each with their benefits and challenges27. In a spontaneous metastasis model, a
primary tumor is genetically induced or injected into an orthotopic or subcutaneous site
and the animal is observed over time to identify signs of metastatic disease. The
spontaneous metastasis model is the most clinically relevant of current models used, as it
most closely mimics patient disease, with primary tumor development followed by
metastatic progression. The major drawback, however is establishing a timeline of
metastasis formation so that tissues can be analyzed at the best stage of metastasis
development. In well-established models, the timing of metastatic progression is known
and animals can be sacrificed at essential time-points, but establishing this information
takes a great deal of time and a large number of animals. Additionally, spontaneous
metastasis models generally take an extensive length of time to allow for primary tumor
development and then metastatic progression. Finally, the inability to measure the
number of cells that have been shed to distant organs makes the spontaneous metastasis
model difficult to quantify. To address these shortcomings, experimental metastasis
models were developed. In these models, cells are introduced as a suspension directly
into the circulation, with the site of injection varying by the organ of interest. To
investigate lung metastasis cells are injected via the lateral tail vein. To target the liver,
cells are injected via the mesenteric vein and for a global analysis of metastatic outcome,
cells are injected via the left ventricle of the heart. Experimental metastasis models
mimic the shed of cells into the vasculature and allow for direct quantification of the
number of cells that survive and begin to grow27. Additionally, co-injection of a known
ratio of inert micron-sized beads (microspheres) enables comparison between time-points
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to determine the proportion of injected cells that progress from single cells to
micrometastases to macrometastases28, 29. The major drawback of these models is that
they inject a large bolus of cells at a single time, rather than truly mimicking a steady
release of cells into the vasculature as is seen clinically. They also bypass the earliest
stages of metastasis where cells leave the primary tumor and enter the vasculature.
Additionally, the potential impact that a primary tumor may have on metastatic
progression is unable to be investigated.
The data presented in Chapter 3 and 4 indicates that pre-clinical investigation of
metastasis without the presence of a primary tumor does not allow for analysis of all
potential players involved. Evaluation of metastasis using both spontaneous and
experimental metastasis models is essential, but may not be the most relevant, especially
when testing new therapeutic agents. It is possible that the effect of the agent on
metastasis would be tempered by the presence of a primary tumor. Yet relying on a
spontaneous model for this type of investigation would be further complicated by the
effect that the agent was having on the primary tumor itself. Analysis of a new agent in a
spontaneous metastasis model would potentially lead to a reduction in metastasis, but this
reduction would be less easily understood due to potential reduction in primary tumor
size. Additionally, the step in metastasis affected by the therapeutic would be difficult to
identify. Therefore, the use of a model that provides both the primary tumor and the
ability to quantify and analyze metastatic outcome through a bolus injection of a known
number of cancer cells may provide information not available when utilizing a
spontaneous or experimental model alone.
This thesis identifies the ability of a primary tumor to restrict metastatic growth in two
well-studied cell lines. Interestingly, the mechanism behind the identified concomitant
tumor resistance does not align with the more commonly reported mechanisms, rather it
provides insight into the extensive role that the host hemostatic system plays in
metastasis. Also, previous studies have shown that both the B1615 and MDA-MB-23117
cell lines can instead stimulate metastasis progression through release of specific factors
that cause BMDC mobilization to the primary tumor site or to the pre-metastatic niche.
Identification of an increase in VEGFR1+ cells in the lung of 231LN-scr primary tumor-
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bearing animals indicates that it is possible that the 231LN (and perhaps also the B16F10)
primary tumors are causing BMDC mobilization, but that the significant role of
hemostasis in metastasis formation is able to over-ride any benefit provided by the
recruited BMDC.

5.2.3 Clinical implications
The work presented in this thesis emphasizes that changes in patient homeostasis are not
just an unfortunate complication of malignancy. Rather, clinical identification of VTE or
other thrombotic events indicates that the host hemostatic system is being engaged by a
primary tumor or metastatic cells. These changes lead to the morbidity and mortality
associated with thrombotic events, but also to alterations in tumor progression. It is also
important to recognize that due to the holistic nature of metastatic disease, treatment of
one facet of patient health can have an impact on overall patient outcome, potentially
beyond the expected mechanism of the treatment. As shown in Chapter 2, treatment of
cancer patients undergoing surgery to remove a primary tumor with an anti-fibrinolytic
agent will likely reduce the risk of blood loss and transfusion requirements during
surgery30, but may also lead to increased metastasis of those cells shed from the primary
tumor. Additionally, development of chemotherapy-induced thrombocytopenia is treated
quickly to restore normal platelet numbers31. The work presented in Chapter 3 would
suggest that maintaining low platelet numbers could significantly reduce metastatic
progression. Additionally, chemotherapeutic efficacy has been found to be increased in
thrombocytopenic animals due to increases in vascular permeability allowing for
increased drug delivery32. Induction of thrombocytopenia led to increased tumor
hemorrhage, but no other blood loss, and allowed for a 40% increase in drug localization
in the tumor. Therefore, though thrombocytopenia represents a significant complication
in patient treatment, it may also provide an opportunity to increase therapeutic efficacy.
In evaluating overall status of disease in a cancer patient, platelets represent a particularly
valuable resource. Platelets are known to actively sequester VEGF, platelet factor 4 and
TSP released from tumor cells33. It has been noted that despite normal levels in the
plasma or serum of the patient, platelet levels of these factors are already elevated, even
when tumors are < 1 mm34. Therefore, analysis of platelet granules to identify markers of
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aggressive disease could provide advance notice of pending disease progression.
Additionally, several clinical studies have identified an improvement in cancer patient
outcome following long term treatment with anti-coagulants, especially for those patients
without metastases at time of entry to the clinical trial35.
This thesis suggests that identification and treatment of malignancy-associated
complications should be investigated beyond the symptom alone. Each change in overall
patient well-being could represent a progression in disease state. Overall, this thesis
illustrates that metastasis is a complex process that is affected by a balance of interplay
between tumor and host factors. Investigation of individual proteins on tumor cell
behavior in vitro, while necessary, is not sufficient to identify the true mechanisms
behind disease progression. Many competing influences exist in vivo, therefore
investigation of cancer progression in model systems that most closely mimic the clinical
situation is essential. Through understanding of the effect of cancer on the host, novel
treatments that prevent the exploitation of the host by tumor cells or bolster hostmediated tumor cell killing could be developed.

5.3 Future directions
The focus of cancer metastasis research has previously been on the innate properties of
tumor cells which allow for successful metastasis. As described in this thesis, the
interaction between a primary tumor, the host and metastatic cells is extensive and can be
a major determinant of disease progression. The innate characteristics of a tumor cell
that lead to successful metastasis may in fact be those that provide the cell the ability to
exploit host systems and tissues. Through identification of the major components of the
host which are involved in metastasis, such as the hemostatic system, novel
characteristics and important attributes of aggressive tumor cells will be identified, and
could provide novel treatment avenues.
The concept of concomitant tumor resistance has been recognized for decades13, yet has
not been fully evaluated to determine the potential mechanisms behind the extensive
metastatic inhibition identified. Importantly, concomitant tumor resistance does not
represent simply a pre-clinical phenomenon, as it has been found in cancer patients that
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resection of a primary tumor can lead to an explosive outgrowth of previously undetected
metastases (reviewed in 36). As discussed in Chapter 4, the timing of breast cancer
recurrence may indicate a synchronization of tumor cell growth that aligns with tumor
resection37. Through investigation of concomitant tumor resistance, understanding of the
process of angiogenesis was fundamentally altered by identification of angiogeneisis
inhibitors38. Unfortunately, these inhibitors did not show great clinical success, yet the
understanding gained has revolutionized understanding of normal and tumor
angiogenesis and metastasis.
In this thesis, I identified that two different tumor cell lines are capable of inducing
concomitant tumor resistance. It is known that the presence of cancer can alter the host
hemostatic system but it has not been previously recognized that a primary tumor could
restrict metastatic growth through manipulation of hemostasis. Therefore the mechanism
behind this inhibition of metastasis does not align with previously elucidated mechanisms
of concomitant tumor resistance involving immune-mediated rejection of metastatic cells
or growth suppression through anti-angiogenic factors released from the primary tumor.
The B16F10 cell line is non-immunogenic, and the 231LN cells are grown in
immunocompromised mice, therefore exposure to the primary tumor would not be
expected to increase surveillance of secondarily injected cells. Additionally, in both the
B16F10 and 231LN model, animals were sacrificed at an early time-point following the
second injection. Developing metastases remained very small (18000 µm3 and 300 µm3
respectively) and were well below the 1 mm size where a tumor must recruit its own
vasculature39, 40. Therefore, anti-angiogenic factors released from the primary tumor
would not yet have had an effect on metastatic establishment. Changing perspective and
considering malignancy as a holistic disease will aid current understanding of the tumor
impact on the host, and could lead to different treatment avenues. Thorough
investigation of the impact of a primary tumor on metastasis of secondarily injected cells
will provide great insight into potential new means to restrict metastatic growth. It is
essential to understand the relationship between concomitant tumor resistance and premetastatic niche formation. It is likely that differential expression of key factors will lead
to either metastatic inhibition or promotion; it is essential that these factors be identified
and investigated to determine their role in clinical cancer progression. Interestingly, OPN
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expression has been linked with BMDC mobilization16, and the MDA-MB-231 cell line
has been found to stimulate pre-metastatic niche formation, leading to increased
metastasis17. In this thesis we show that using a variant of the MDA-MB-231 line
(231LN), there is an increased number of VEGFR1+ cells present in the lungs of primary
tumor-bearing animals, and induced larger clusters of these cells than in tumor-naïve
animals. These clusters were often associated with tumor cells and may indicate the
presence of a pre-metastatic niche, yet no overall increase in metastasis was identified. It
appears that the metastatic inhibition induced by the primary tumor is able to overcome
the promotion of metastasis by the presence of VEGFR1+ cell clusters. This difference in
metastatic outcome as compared with previously published reports15, 17 may be due to
differences in the mouse strain used, but if these two related cell lines show a similar
pattern of metastasis-promotion or -inhibition when grown in the same mouse strain then
they present a great opportunity. Given the similar heritage of these cell lines, direct
comparison of gene expression patterns could provide great insight into the factors
essential for either concomitant tumor resistance and/or pre-metastatic niche formation.
Additionally, investigation of the effect of a primary tumor on secondary metastasis
should be investigated using primary tumors that have both high and low OPN
expression. The MDA-MB-435 cells would be a valuable model in this regard, as it has
been shown that shOPN transfection results in complete abrogation of OPN expression41.
Additionally, these cells are known to express TF, therefore the role of hemostasis
identified here would be preserved42.
Cancer exists and progresses through interaction and manipulation of host tissues,
systems and responses. Only through understanding the effects of a developing
malignancy on normal host biology will the process of metastasis be thoroughly
understood. This understanding will provide insight into new avenues of treatment and
will significantly improve disease management and disease outcome.

124

1. Crissman JD, Hatfield J, Schaldenbrand M, Sloane BF, Honn KV. Arrest and
extravasation of B16 amelanotic melanoma in murine lungs. A light and electron
microscopic study. Lab Invest 1985;53:470-8.
2. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL,
Bugge TH. Fibrinogen is an important determinant of the metastatic potential of
circulating tumor cells. Blood 2000;96:3302-9.
3. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL.
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or
angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-72.
4. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck
KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating
hemostatic factors cooperate to increase metastatic potential through natural killer celldependent and-independent mechanisms. Blood 2007;110:133-41.
5. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck
KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by
impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-85.
6. Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to
inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional
effects. Thrombosis research 2007;120 Suppl 2:S107-11.
7. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, Muschel RJ.
Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early
metastatic colony formation. Cancer Res 2004;64:8613-9.
8. Boeryd B, Hagmar B, Johnsson G, Ryd W. Effects of EACA, AMCHA and
guanethidine on metastases induced by intravenously injected tumour cells. Pathol Eur
1974;9:119-23.
9. Uetsuji S, Yamamura M, Takai S, Hioki K, Yamamoto M. Effect of aprotinin
on metastasis of Lewis lung tumor in mice. Surg Today 1992;22:439-42.
10. Giraldi T, Nisi C, Sava G. Lysosomal enzyme inhibitors and antimetastatic
activity in the mouse. Eur J Cancer 1977;13:1321-3.
11. Stein-Werblowsky R. On the prevention of haematogenous tumor metastases
rats. The role of the proteinase inhibitor "Trasylol". J Cancer Res Clin Oncol
1980;97:129-35.
12. Turner GA, Weiss L. Analysis of aprotinin-induced enhancement of
metastasis of Lewis lung tumors in mice. Cancer Res 1981;41:2576-80.
13. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor
challenge. Advances in cancer research 1983;39:71-120.

125

14. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche.
Cancer Res 2006;66:11089-93.
15. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C,
MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, et al. VEGFR1-positive
haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature
2005;438:820-7.
16. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA,
Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA. Systemic endocrine
instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005.
17. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia
AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment
to form the premetastatic niche. Cancer Cell 2009;15:35-44.
18. Folkman J. Angiogenesis inhibitors generated by tumors. Molecular medicine
(Cambridge, Mass 1995;1:120-2.
19. Gorelik E. Resistance of tumor-bearing mice to a second tumor challenge.
Cancer Res 1983;43:138-45.
20. Oncology Animal Models, vol. 2011 Wilmington, MA: Charles River
Laboratories International, Inc., 2011:Information package on immunocompromised
mice.
21. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT,
Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature
2006;440:1222-6.
22. Berny-Lang MA, Aslan JE, Tormoen GW, Patel IA, Bock PE, Gruber A,
McCarty OJ. Promotion of experimental thrombus formation by the procoagulant activity
of breast cancer cells. Phys Biol;8:015014.
23. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic
mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
24. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and
anticoagulation on cancer and cancer survival. J Clin Oncol 2009;27:4902-11.
25. Milsom C, Rak J. Tissue factor and cancer. Pathophysiol Haemost Thromb
2008;36:160-76.
26. Tilley RE, Holscher T, Belani R, Nieva J, Mackman N. Tissue factor activity
is increased in a combined platelet and microparticle sample from cancer patients.
Thrombosis research 2008;122:604-9.

126

27. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis
2005;26:513-23.
28. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom
AC, Chambers AF, MacDonald IC. Temporal progression of metastasis in lung: cell
survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res
2000;60:2541-6.
29. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers
AF, Groom AC. Multistep nature of metastatic inefficiency: dormancy of solitary cells
after successful extravasation and limited survival of early micrometastases. The
American journal of pathology 1998;153:865-73.
30. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B,
Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic
blood transfusion. Cochrane Database Syst Rev 2007:CD001886.
31. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia:
current status of thrombopoietic agents. Semin Hematol 2009;46:S26-32.
32. Demers M, Ho-Tin-Noe B, Schatzberg D, Yang JJ, Wagner DD. Increased
efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res
2011;71:1540-9.
33. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, Italiano JE,
Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, et al. Platelets actively
sequester angiogenesis regulators. Blood 2009;113:2835-42.
34. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis.
Nat Rev Cancer;11:123-34.
35. Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl
Sci;93:335-49.
36. Coffey JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG, Redmond HP.
Excisional surgery for cancer cure: therapy at a cost. The lancet oncology 2003;4:760-8.
37. Retsky M, Demicheli R, Hrushesky WJ. Does surgery induce angiogenesis in
breast cancer? Indirect evidence from relapse pattern and mammography paradox. Int J
Surg 2005;3:179-87.
38. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane
WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that
mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
39. Folkman J. Incipient angiogenesis. Journal of the National Cancer Institute
2000;92:94-5.

127

40. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases:
balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat
Med 1995;1:149-53.
41. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost
AR, Welch DR. Osteopontin knockdown suppresses tumorigenicity of human metastatic
breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006;23:123-33.
42. Sun L, Lin S, Zhao R, Yu B, Yuan S, Zhang L. The saponin monomer of
dwarf lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration
during hypoxia via regulation of tissue factor. Biol Pharm Bull;33:1192-8.

128

Appendices

129

Appendix A: Copyright Agreements and Approvals for Previously Published Work

130

Correspondence regarding copyright for Chapter 2, published as “Effect of antifibrinolytic therapy on experimental melanoma metastasis” by JM Kirstein, KC Graham,
LT MacKenzie, DE Johnston, LJ Martin, AB Tuck, IC MacDonald, and AF Chambers in
Clinical and Experimental Metastasis 2009;26(2):121-31.
Jenn Kirstein
To:

Hello Dr Ruiz,

I have an article published in the journal 'Clinical and Experimental
Metastasis' and am seeking permission to use that article as part of
my PhD thesis.

The article is "Effect of anti-fibrinolytic therapy on experimental
melanoma metastasis, Kirstein JM, Graham KC, Mackenzie LT, Johnston
DE, Martin LJ, Tuck AB, MacDonald IC, Chambers AF., Clin Exp
Metastasis. 2009;26(2):121-31".

Thank you,

Jenn

Jennifer Kirstein
PhD candidate
Department of Medical Biophysics
University of Western Ontario
London Ontario Canada

Fri, Feb 18, 2011 at 2:30 PM

131

Ruiz, Melania, Springer SBM NL
To: Permissions Europe/NL
Cc: Jenn Kirstein

Dear Colleague,

Could you please help Jennifer with her below request?

Thank you,
Melania
Melania Ruiz
Springer Science+Business Media B.V.
Publishing Editor
Cancer Research
Life Sciences - Biomedical Unit
Van Godewijckstraat 30 | 3311 GX
Office Number: 07C14b
P.O. Box 17 | 3300 AA
Dordrecht | The Netherlands

Mon, Feb 21, 2011 at 2:21 AM

132

Permissions Europe/NL

Tue, Feb 22, 2011 at
6:17 AM

To:

Dear Madam,

With reference to your request (copy herewith) to reprint material on which Springer Science and
Business Media controls the copyright, our permission is granted, free of charge, for the use indicated
in your enquiry.
This permission
-

allows you non-exclusive reproduction rights throughout the World.

-

permission includes use in an electronic form, provided that content is
* password protected;
* at intranet;

-

excludes use in any other electronic form. Should you have a specific project in mind, please

reapply for permission.
-

requires a full credit (Springer/Kluwer Academic Publishers book/journal title, volume, year of

publication, page, chapter/article title, name(s) of author(s), figure number(s), original copyright
notice) to the publication in which the material was originally published, by adding: with kind
permission of Springer Science and Business Media.
The material can only be used for the purpose of defending your dissertation, and with a maximum
of 100 extra copies in paper.
Permission free of charge on this occasion does not prejudice any rights we might have to charge for
reproduction of our copyrighted material in the future.

Best regards,

Nel van der Werf (Ms)
Rights and Permissions/Springer
Van Godewijckstraat 30 | P.O. Box 17
3300 AA Dordrecht | The Netherlands

133

Correspondence regarding text chapter entitled: Interactions of Normal Tissues and
Systems with Metastatic Cells: Impact on Location, Survival and Growth” to be included
in “Experimental and Clinical Metastasis: A Comprehensive Review”, Springer, In Press.
________________________________________
From: Ann Chambers
Sent: February 17, 2011 4:01 PM
To: Julia Burnier
Subject: RE: RE: Book Chapter

Hi Julia -

Any further word on this chapter or the correct citation.

Jenn is in the process of writing up her PhD thesis and would like to list this as an in
press citation, if possible.

Thanks.
Ann

134

________________________________________
From: Julia Burnier
Sent: February 18, 2011 7:10 AM
To: Ann Chambers
Cc: Miguel N. Jr. Burnier, Dr.; Tiffany Porraccio;
Subject: RE: RE: Book Chapter

Dear Dr. Chambers,

Since our last contact, I have moved from the Henry C. Witelson Laboratory to Spain to
pursue my postdoc. I therefore CC-ed all those with the information regarding the book,
the citation, and any other future information you may need regarding our collaborative
book. Tiffany, could you kindly ask Springer for the correct citation and send it to Dr.
Chanbers?

I think it is ok for Jenn to cite the book as "in press" since it was a request from Springer
and is currently being edited by them. Tiffany, perhaps you can double check this as
well.

Please send my congratulations to Jen on finishing her degree.

With warm regards
Julia

135

From: Tiffany Porraccio
To: Ann Chambers
Date: Mon, 21 Feb 2011 11:19:09 -0500
Subject: RE: RE: Book Chapter
Dear Dr. Chambers,

I will be in contact with all the authors this week to give them an update on the book and
how to correctly cite it. As for an update, we have submitted the chapters to Springer and
will finalize soon. The correct citation is "Experimental and Clinical Metastasis: A
Comprehensive Review - In Press (Springer)", as was suggested by Julie, it is correct to
write In Press after the title.

If you need anything else, please do not hesitate to contact me.

Best regards,
Tiffany

Tiffany Porraccio
Research Assistant
Henry C. Witelson Ocular Pathology Laboratory
3775 University, Room 216
Montreal (Quebec) Canada H3A 2B4

136

Appendix B: Animal Experimentation Ethics Approval

137

138

139

Curriculum Vitae

Name:

Jennifer Maclean, nee Kirstein

Post-secondary
Education and
Degrees:

University of Western Ontario
London, Ontario, Canada
1999-2003 BSc Honors Genetics with Distinction
The University of Western Ontario
London, Ontario, Canada
2003-2005 MSc Candidate, Department of Medical Biophysics
The University of Western Ontario
London, Ontario, Canada
2005-2011 PhD Candidate, Department of Medical Biophysics

Honours and
Awards:

Breast Cancer Society of Canada Studentship, Feb 2010-Jun 2011
Breast Cancer Society of Canada Studentship, Sep 2009-Jul 2009
Graduate Student Research Grant, UWO, Dec 2008
National Cancer Institute of Canada, Terry Fox Foundation Young
Investigator Travel Grant, Aug 2008
Natural Sciences and Engineering Research Council of Canada,
Postgraduate Scholarship, PhD, Sep 2005-Aug 2008
Oncology Research Day Poster Award, May 2007, May 2004
Oncology Research Day Oral Presentation Award, May 2005
Natural Sciences and Engineering Research Council of Canada,
Canada Graduate Scholarship, MSc, Sep 2004-Aug 2005
Breast Cancer Society of Canada Studentship, Sep 2003-Aug 2005
Ontario Graduate Scholarship, May 2003-Aug 2004
Natural Sciences and Engineering Research Council of Canada,
Undergraduate Research Award, May 2002-Aug 2002
Louis H. Simmons Continuing Scholarship, Sep 2000-Apr 2003

Related Work
Experience

Business Development Specialist, London and Windsor Region
MITACS
Jan 2011-Present
Assisted companies and organizations in the development of new
research initiatives, identified appropriate academic expertise, and
facilitate partnership between industy and academic researchers.

140

Graduate Seminar Coordinator:
Department of Medical Biophysics
Sep 2006-May 2010
Organized graduate research seminars, including presentation
schedule, room bookings, and notification of fellow students
regarding presentation guidelines and submission deadlines.
Teaching Assistant:
Medical Sciences Laboratory.
Jan-Apr 2008, Jan-Apr 2009
Assisted 4th year students in laboratory course focusing on animal
model of atherosclerosis.
Biological Macromolecules. Sept-Dec 2004, Sept-Dec 2005
Presented weekly lecture-style tutorial sessions on course material.
Maintained course webpage with question/answer forum.
Undergraduate Supervisor:
Department of Medical Biophysics. May 2007-Apr 2008
Guided 4th year research student through project development and
data interpretation to ensure fulfillment of course and graduation
requirements.
Publications: (listed under maiden name „Kirstein‟)
Kirstein, JM and Chambers AF. Interactions of Normal Tissues and Systems with
Metastatic Cells: Impact on Location, Survival and Growth. In: Metastases: From the
Bench to the Bedside, Editors: J Burnier and MN Burnier, Springer. In Press, August
2010.
Kirstein JM, Hague MN, McGowan PM, Graham, KC, Chambers AF. Primary
melanoma tumor decreases metastasis through alterations in systemic coagulation.
Manuscript Submitted to Cancer Research, September 2010.
McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic
outgrowth: clinical issues and experimental approaches. Future Oncology, 2009;
5(7):1083-98.
Kirstein JM, Graham KC, Mackenzie LT, Johnston DE, Martin LJ, Tuck AB,
MacDonald IC, Chambers AF. Effect of anti-fibrinolytic therapy on experimental
melanoma metastasis. Clinical & Experimental Metastasis, 2009;26(2):121-31.

141

Professional
Development:

Public Science in Canada: Strengthening Science and Policy to
Protect Canadians. May 12-14, 2010, Gatineau, Quebec.
Gained further understanding of national science policy and
established contacts with federal scientists.
Student-2-Business Networking Conference. Jan 28, 2010,
London, Ontario
Connected with London‟s business and community representatives
and discovered many industry players within London.
Public Science in Canada: Strengthening Science to Protect
Canadians. Sept 6-7, 2007, Gatineau, Quebec.
Attended conference to discuss the role of public science in
Canada and gained insight into national science policy.
Coordinator - Careers Beyond Academia: UWO, Faculty of
Medicine and Dentistry, May 2007-Apr 2008.
Spearheaded and organized the first career day for MSc and PhD
students looking for career opportunities outside of academia.
Moderated panel discussion with students and federal government
representatives.

